





SEX DIFFERENCES IN GENE EXPRESSION AND PAIN-RELATED 





Nicholas Ling Stucky 
 
B.S., Yale College, 2001 
M.S., University of Washington, 2005 
Submitted to the graduate degree program in Pharmacology, Toxicology, and 
Therapeutics and the Graduate Faculty of the University of Kansas in partial 




             
Nancy E.J. Berman, Ph.D., Co-Chair 
 
 
        
Kenneth E. McCarson, Ph.D., Co-Chair 
 
 
        
S. J. Enna, Ph.D. 
 
 
        
Sara A. Li, Ph.D. 
 
 
        
Thomas L. Pazdernik, Ph.D. 
 
 
        
Douglas E. Wright, Ph.D. 
 





The dissertation committee for Nicholas Ling Stucky certifies that this is the 
approved version of the following dissertation: 
 
 
SEX DIFFERENCES IN GENE EXPRESSION AND PAIN-RELATED 







        
Nancy E.J. Berman, Ph.D. (Co-Chair) 
 
 
        
Kenneth E. McCarson, Ph.D. (Co-Chair) 
 
 
S. J. Enna, Ph.D. 
 
 
Sara A. Li, Ph.D. 
 
 
Thomas L. Pazdernik, Ph.D. 
 
 


















I would like to thank my two mentors Dr. Nancy Berman and Dr. Ken 
McCarson for their guidance and advice as I have pursued this degree. 
Countless conversations with Dr. Berman about science, academia, and life have 
informed my view of the field and the world. Dr. McCarson has always been 
available to answer questions about science, intractable problems ranging from 
behavioral assays to departmental protocol, or navigating the rigors of the 
graduate life. 
I want to thank my committee members Dr. Sam Enna, Dr. Sara Li, Dr. 
Tom Pazdernik, and Dr. Doug Wright. They have been everything I would want 
from a committee: intelligent, available, and thorough. 
Members of my lab have been indispensible. Eugene Gregory, Dr. Chris 
Liverman, Dr. Rachel Williams, Dr. Rajat Sandhir, and Jordan Taylor thank you. I 
am very grateful to the support staff that also made this possible including 
Michelle Winter and Dr. Hong Yu He and to Pharmacology Department staff and 
KIDDRC staff.  
Finally I would like to thank my family, my parents Rick and Debbie 
Stucky, my sister Shata and her husband Luke, and my brother Dan and his wife 
Ashley. They have always been very supportive of all my endeavors and have 
offered invaluable support as I pursued this work. Thank you to my friends in 
Kansas City and around the world who have kept my spirits high and helped me 





Many laboratory animal studies of migraine have employed 
electrophysiological techniques to assess neuronal sensitization, but few have 
examined behaviors using International Headache Society criteria, which are 
based on behavioral changes including duration and intensity of pain and 
avoidance of routine activity. Fewer still have attempted to correlate the 
appearance of these diagnostic symptoms with changes in the activity of pain-
related neurotransmitters and neuromodulators, such as calcitonin gene related 
peptide (CGRP). A vasoactive neuropeptide, CGRP might contribute to the 
vasodilatory component of migraine, and to the pain associated with this 
condition as it is present in nociceptors, including those in the trigeminal ganglion 
that innervate cerebral vasculature. Previous work has shown that CGRP levels 
are increased in animal models of inflammatory pain and in the external jugular 
vein of humans during migraine attacks. The CGRP receptor is comprised of 
three proteins: a G–protein coupled receptor called calcitonin-like receptor (CLR), 
a receptor activity-modifying protein (RAMP1), and a coupling protein, receptor 
component protein (RCP). Thus, the availability and sensitivity of this receptor is 
subject to regulation at numerous levels. 
The objectives of this study were to develop a preclinical behavioral model 
of chronic migraine, to test sensory and motor behaviors relevant to International 
Headache Society diagnostic criteria, to examine whether there are sex 
differences in these behaviors, and to assess whether alterations in the 




associated with sex differences or changes in pain-related behaviors. 
Male and female Sprague-Dawley rats were implanted with a dural 
cannula placed over the occipital cortex. Groups of rats were treated with 10 or 
20 microliter volumes of an inflammatory soup containing 1 mM each of 
histamine, serotonin, and bradykinin, as well as 0.1 mM prostaglandin E2 (pH 
5.5). A control group received sterile phosphate-buffered saline (pH 7.4) alone. 
Baseline behavioral testing was conducted on all eight groups of animals prior to 
surgery and seven days later. The inflammatory soup or control solution was 
administered supradurally 3 times/week for a total of eight applications. 
Locomotor activity was assessed using force plate actimetry during and following 
application of the inflammatory soup or vehicle. Total RNA was isolated from 
ipsilateral trigeminal ganglia and ipsilateral medulla. Real-time polymerase chain 
reaction was used to quantify the expression of amplified constructs using gene 
specific primers for CGRP, RAMP1, CLR, and RCP.  
 The results reveal pronounced sex differences in behavior following 
application of the inflammatory soup. Female rats displayed dose-dependent 
migraine-related behaviors and a longer duration of these effect in 
measurements of distance traveled, bouts of low mobility, and spatial 
confinement. Both males and females experienced allodynia following exposure 
to the inflammatory mixture. Moreover, females displayed a higher baseline gene 
expression of CGRP and lower baseline gene expression of RAMP1, CLR, and 
RCP in the medulla than male animals. In addition to these baseline differences, 




not in males. No sex difference in CGRP gene expression was noted in the 
trigeminal ganglia, although females do have a lower baseline expression of 
CGRP receptors, RAMP1, CLR, and RCP than males. It was also found that in 
the trigeminal ganglia RAMP1, CLR and RCP are inducible, especially in males, 
and that at least a portion of these responses are the result of volume effects 
associated with application to the dura of the inflammatory soup or vehicle.  
These findings indicate significant sex dependent changes in rat 
locomotor activity and CGRP-related gene expression in the brainstem and 
trigeminal ganglia associated with the application to the dura of an inflammatory 
soup. As the behavioral endpoints utilized in this study correspond to clinical 
signs considered by the International Headache Society as diagnostic for 
migraine, these data confirm that CGRP and its receptors are involved in 
migraine pathophysiology and reveal for the first time that alterations in the 
response to this peptide may be related to the increased prevalence of migraine 
in females. Such findings could be of value in devising new therapeutic strategies 
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Historical context for migraine 
 The earliest evidence for migraine come from skulls exhumed from the 
Andean region of South America. The skulls show early Peruvian societies 
practiced neurosurgery over 8000 years ago. While the exact reasons for this 
neurosurgery are not known, it is likely that some of these operations were aimed 
at relieving headache (Marino and Gonzales-Portillo, 2000). These societies also 
practiced intentional cranial deformation to modify the growth axis in infancy 
perhaps to differentiate different social classes (Schijman, 2005). It is possible 
that increased intracranial pressure in regions of the cerebral cortex necessitated 
trephination for relief of pressure and headache symptoms (Gerszten et al., 
1998). We know trephination was recommended as treatment for migraine as 
late as the 17th century by the famous British physician William Harvey 
(Rapoport and Edmeads, 2000).  
Migraine is mentioned in the oldest extant medical text, the Ebers 
Papyrus, which was written in the mid 15th century (Garcia-Albea, 1999). In this 
text migraine is described as being caused by “pain-matter demons”, with 
magical and surgical techniques being the prescription for punishing and 
protecting against this demon power; the suggested remedy: “for pains in one 
side of the head. Skull of catfish; were heated until they turned to ashes and 
boiled with oil; the head is rubbed therewith for four days” (Karenberg and Leitz, 
2001). Catfish was thought to represent the demon sphere and burning it may 
have been intended to destroy its power. Other techniques used involved binding 




patient’s head. It is possible that the act of binding may have offered some relief 
by compressing the cranial blood vessels of the external carotid system 
(Rapoport and Edmeads, 2000). Greek and Roman cures for headache 
employed similar prescriptions (Karenberg and Leitz, 2001), with head binding 
being one of the standard treatments for migraine well into the 19th century 
(Rapoport and Edmeads, 2000). 
Hippocrates (circa 400 BCE) was one of the first to report vomiting and 
visual aura, two hallmark symptoms for the diagnosis of migraine today. He 
described a young patient who experienced a bright light in his right eye and 
whose symptoms were relieved through vomiting. Hippocrates was among the 
first to understand that migraine was caused by a physical imbalance in the body 
and not by some supernatural force. He mentions that migraines are caused by 
the pathologic rise of vapors from the liver to the head. He also identified 
migraine as benign and advocated as treatment cessation of activities which 
appeared to trigger the headache pain (Rapoport and Edmeads, 2000). 
Galen (200 CE) was able to glean a great deal of medical and anatomical 
information from animal dissections and trauma surgeries on gladiators. He 
generally followed Hippocratic theory on the origin of migraine and is believed to 
have coined the term that lead to the word “migraine”. His term for the disorder 
was the ancient Greek word “hemicrania” which became the Old English term 
“migrem” which was ultimately transformed by the French to “migraine” 
(Rapoport and Edmeads, 2000; Waeber and Moskowitz, 2003).  




understanding of migraine beyond the knowledge imparted by the Greeks with 
his publication of “The London Practice of Physick.” He states in this tome that 
headache pain must be associated with the “parts of the Head that are most 
nervous, that is, the nerves themselves.” The meninges were considered 
“nervous”, while he noticed that the cerebral cortex, cerebellum, and brainstem 
“want sensible fibers” and remained pain-free when distended (Rapoport and 
Edmeads, 2000). Later he noted that the cerebral and meningeal vasculature 
was heavily innervated and hypothesized that migraine is caused by cranial 
vasodilation. This speculation led to the vascular theory of migraine. 
Modern diagnosis 
Migraine is considered a syndrome, reflecting the current lack of 
understanding about the underlying pathology of this condition. Currently, 
migraine is characterized as a collection of idiopathic symptoms that, taken 
together, are labeled migraineous. At present the symptomatic diagnosis of 
migraine is made on the basis of International Headache Society (IHS) criteria 
(IHS, 2004).  
Migraine without aura 
Menstrual migraines are classified within the grouping of migraine without 
aura because they are not typically accompanied by it. The IHS diagnosis for 
migraine without aura is defined as follows: 
At least five headache attacks lasting 4 - 72 hours (untreated or 
unsuccessfully treated), and has at least two of the four following characteristics: 




2. Pulsating quality 
3. Moderate or severe intensity (inhibits or prohibits daily activities) 
4. Aggravated by walking stairs or similar routine physical activity 
During headache at least one of the two following symptoms must occur: 
1. Phonophobia and photophobia 
2. Nausea and/or vomiting 
Migraine with aura 
Classical migraine has the additional symptom of aura. According to the 
IHS, a migraine with aura must meet the following diagnostic criteria: 
At least two attacks fulfilling at least three of the following: 
1. One or more fully reversible aura symptoms indicating focal cerebral 
cortical and/or brain stem functions 
2. At least one aura symptom develops gradually over more than four 
minutes, or two or more symptoms occur in succession 
3. No aura symptom lasts more than 60 minutes; if more than one aura 
symptom is present, accepted duration is proportionally increased 
4. Headache follows aura with free interval of at least 60 minutes (it may 
also simultaneously begin with the aura) 
At least one of the following aura features establishes a diagnosis of 
migraine with typical aura: 
1.  Homonymous visual disturbance 
2.  Unilateral paresthesias and/or numbness 




4.  Aphasia or unclassifiable speech difficulty 
Although the temporal progression of migraine is not consistent across 
patients, it can be divided into several stages. The first stage, the prodrome or 
premonitory phase, can last many hours and consists of feelings of uneasiness, 
heightened perception, and fluid retention. In the classical description of migraine 
the prodrome is followed by a visual aura. Some believe that the aura can also 
be manifested in the sensory perceptions if the disturbance is located in the 
sensory cortex. The aura may last for up to 30 minutes. At the conclusion of the 
aura the migraineur enters the headache phase which may be accompanied by 
nausea, vomiting, pallor, photophobia, and phonophobia. This phase can persist 
for hours or days and is most commonly resolved by sleep. After resolution, 
migraineurs enter the postdrome phase, which is often referred to as the 
postdromal hangover. During this phase migraineurs may feel tired, have limited 
food tolerance, and experience diuresis (Blau, 1992). 
Epidemiology of migraine 
Migraine has a strong genetic component. Several studies place the 
heritability of migraine at up to 50% (Kors et al., 2004; Pietrobon, 2005). 
Interestingly, migraines with aura seem to show a higher genetic component than 
those without aura. One rare, but well studied, inherited form of migraine is 
Familial Hemiplegic Migraine (FHM). This condition shows an autosomal 
dominant inheritance pattern and is associated with genes CACNA1A and 
ATP1A2 in FHM type 1 and FHM type 2, respectively. The CACNA1A gene 




Na+/K+ ion pump (Kors et al., 2004).  
The prevalence of migraine, which is higher in women than men, is 
approximately 13% of the population according to studies performed in the 
United States and Europe (Linde, 2006). The 1-year prevalence of migraine 
among men is 6–9% , whereas it is 15–17% among women (Linde, 2006). The 
sex disparity of prevalence begins at puberty, increases during the reproductive 
years, and becomes less pronounced after menopause (Stewart et al., 2000a). 
Migraine incidence also decreases during pregnancy especially in the third 
trimester (Chen and Leviton, 1994). The dynamic nature of menstrual migraine 
may provide important insights into the pathophysiology of this condition in 
general. 
Migraine pathophysiology 
Our understanding of migraine remains rudimentary, with considerable 
disagreement among scientists about the etiology of this disorder. Some 
describe migraine pain as unusual and unlike other types of pain. According to 
the generally accepted chronic pain classification system, pain is either 
nociceptive or neuropathic (Merskey, 1986). Nociceptive pain is caused by the 
stimulation of nociceptors by noxious stimuli, and is generally classified as 
thermal, mechanical, or chemical. Stimulation of these pain pathways is thought 
to be the part of a protective healing process in response to tissue damage. 
Neuropathic pain is associated with damage to the nerve itself. This damage may 
result from, for example, trauma, infection, or ischemia. Contrary to the cancer 




al., 2006), efforts are being made to tailor the pain classification system to divide 
nociceptive pain into either inflammatory or dysmodulatory pain (Jensen, 2006). 
In this system inflammatory pain is considered a response to tissue injury and 
subsequent neurogenic inflammation. Signs of inflammation are present in this 
form of pain. Others would prefer to categorize migraine pain as dysfunctional or 
dysmodulatory pain (Figure 1). This classification is quite controversial. In 
dysfunctional pain there are no signs of tissue injury (inflammatory changes) or of 
nerve injury (neuropathic changes). Rather, it is hypothesized that due to a 
poorly understood innocuous event, nociceptive neurons undergo a change and 
transmit signals abnormally. As the stimulus is not, in itself, potentially damaging 
to tissue, it cannot be considered inflammatory and is not neuropathic because 
there is no damage to the nerve itself (Dodick and Silberstein, 2006). 
 









It is accepted that the neurons at the center of migraine pain 
pathophysiology are located in the trigeminal ganglion, alternately referred to as 
the semilunar or gasserian ganglion. This ganglion houses the cell bodies of the 
pseudounipolar neurons of the sensory tract of the trigeminal nerve. The fifth 
cranial nerve, the trigeminal nerve has both motor and sensory components. The 
sensory component of the trigeminal is the exclusive focus of the work presented 
in this report. The sensory component is responsible for transmitting sensory 
information to the central nervous system. The myelinated fibers carry 
information about touch and position while the unmyelinated fibers, termed 
nociceptors, carry information about pain and temperature. Nociceptors are 
thought to be the fibers involved in migraine pain because they transmit the type 
of dull aching pain associated with this condition. The trigeminal neuron transmits 
sensory information from the face, forehead, and scalp. It is comprised of 3 
divisions: the first or ophthalmic division, the second or maxillary division, and the 
third or mandibular division. The ophthalmic division innervates the supraorbital 
regions, the forehead, and scalp, in addition to the meningeal and cranial 
vasculature. The maxillary division innervates the lower eyelid, the cheek, and 
upper lip, whereas the mandibular division innervates the jaw and temporal 
region on the side of the head (Olesen et al., 2006). 
Four regions of the trigeminal vascular system are thought to be involved 
in migraine. One is the cerebral and cranial vasculature where vasodilation is 




antimigraine triptans (Perren et al., 1989; Nilsson et al., 1999), and the calcitonin 
gene-related peptide (CGRP) antagonist, olecegepant (Edvinsson et al., 2002). A 
second is the dura mater and resident inflammatory mast cells which are 
activated by CGRP and subsequently release inflammatory agents and cytokines 
that produce neurogenic inflammation (Theoharides et al., 2005). The third is the 
trigeminal ganglion, which express 5HT1B and 5-HT1D and CGRP receptors (Hou 
et al., 2001) and where CGRP is believed to have an autocrine or paracrine 
action in increasing its own production and in inducing the release of nitric oxide 
and inflammatory cytokines (Li et al., 2008). Another region of the trigeminal 
vascular system thought to be involved in migraine is the second-order sensory 
neurons with their cell bodies located in the spinal trigeminal nucleus of the 
brainstem that express post-synaptic CGRP receptors that can be blocked by 
olecegepant (Storer et al., 2004; Levy et al., 2005). 
Nociceptor function 
Trigeminal nociceptors forward sensory information to the secondary 
neurons in the spinal trigeminal nucleus where it is then transmitted for 
processing in the thalamus and cerebral cortex. These nociceptors are capable 
of both orthodromic transmission and antidromic signaling to peripheral nerve 
terminals. The antidromic signaling is thought to be key in the migraine process. 
At the peripheral terminal, these neurons release neuropeptides such as CGRP 
and substance P (Moskowitz et al., 1979). The neuropeptides then induce 
neurogenic inflammation by inducing mast cell degranulation by binding to 




prostaglandins leads to further inflammation and plasma extravasation. It is 
hypothesized that these chemical substances cause the afferent nociceptors to 
depolarize in response to normally innocuous stimuli, sending a pain signal to the 
spinal trigeminal nucleus and on to the thalamus and cerebral cortex. If the signal 
is sufficiently strong, it can initiate another round of antidromic signaling and 
neuropeptide release, further fueling the vicious cycle of pain and inflammation 
(Moskowitz and Macfarlane, 1993). 
The manner in which the trigeminal neuron is able to affect cranial blood 
vessels was defined further by anatomical studies showing the meninges and 
dural sinus of both humans and laboratory animals are innervated by all three 
branches of the trigeminal nerve (Andres et al., 1987; Moskowitz and Macfarlane, 
1993). These nociceptors are thought to be components of the major pathway for 
transmitting head pain. Interestingly, nonvascular areas of the dura are known to 
be insensitive to pain (Ray and Wolff, 1940; Davis and Dostrovsky, 1986). It has 
only relatively recently that a direct response to noxious stimuli was measured in 
neurons of the cerebral cortex (Hutchison et al., 1999).  
Sensitization 
With respect to pain, sensitization refers to the process whereby the 
threshold for neuronal activation is lowered such that a normally innocuous 
stimulus is capable of activating a response. Sensitization is further defined on 
the basis of its location, with peripheral sensitization involving first order 
afferents. This ability of noxious stimuli to produce long lasting changes in 




sensitization is that which occurs in the brainstem or higher order neurons. 
Central sensitization was first investigated in decerebrate animals where 
contralateral increases in the excitability of spinal cord neurons was observed in 
response to thermal injury (Woolf, 1983). 
 With regard to migraine pain, Strassman and others proposed that 
trigeminal nerve sensitization plays a role in mediating the symptoms of this 
condition. This was demonstrated by the discovery that application of 
inflammatory chemical stimuli to the dura produces depolarization and 
sensitization to mechanical stimulation of afferents that innervate the dural 
venous sinuses. It was hypothesized that once sensitized, these afferents trigger 
vascular changes associated with migraine pain even when they encounter 
normally innocuous mechanical stimuli (Strassman et al., 1996). Since this 
report, electrophysiologists have used a preparation, termed “Inflammatory Soup” 
(IS), which is composed of some of the substances released following mast cell 
degranulation, such as 5-HT, histamine, prostaglandin E2 (PGE2), and bradykinin 
(Strassman et al., 1996) to study the sensitization of primary and secondary 
trigeminal nociceptors. Over the past ten years, many have successfully used IS 
to study central and peripheral sensitization in rodents (Burstein and Jakubowski, 
2004; Oshinsky and Luo, 2006; Jakubowski et al., 2007; Oshinsky and 
Gomonchareonsiri, 2007). 
While mechanisms of peripheral sensitization have been intensively 
studied in spinal sensory neurons (Kessler et al., 1992; Steen et al., 1992; Aley 




trigeminal neurons. Moreover, no studies have attempted to relate migraine-like 
behaviors to increases in CGRP or its receptors in trigeminal neurons. Although it 
is now well-known that central sensitization in the dorsal horn of the spinal cord is 
accompanied by increases in substance P and neurokinin-1 (NK-1) receptors 
(McCarson and Krause, 1994; Krause et al., 1995; McCarson and Krause, 1996; 
Allen et al., 2003; Seybold et al., 2003), virtually nothing is known about possible 
changes in CGRP receptor expression or function in the spinal trigeminal nucleus 
caudalis, even though such alterations could underlie a central sensitization of 
the CGRP system associated with migraine.  
Calcitonin gene-related peptide and migraine 
Sensitization of sensory neurons is associated with increases in 
expression of CGRP, a pro-nociceptive neuropeptide (Nahin and Byers, 1994). A 
splice variant of the calcitonin/CGRP gene (CALCA) (Amara et al., 1982; 
Rosenfeld et al., 1984; Amara et al., 1985), CGRP is released from nerve 
terminals in association with inflammation and inflammatory pain (Devor, 1991b; 
Ohtori et al., 2001; Ohtori et al., 2003; Adwanikar et al., 2007; Benemei et al., 
2007; Tzabazis et al., 2007). Also, CGRP is a potent dilator of meningeal blood 
vessels (Gupta et al., 2006). Other evidence pointing to a possible involvement of 
this peptide in migraine is the fact that CGRP levels increase in the trigeminal 
ganglion following injections of irritants into peripheral targets, and that this 
increase is associated with pain severity (Ambalavanar et al., 2006b). Moreover, 
up-regulation of CGRP occurs within a few hours after application of an 




increase over weeks during chronic inflammation (Ambalavanar et al., 2006b).  
While it has been reported that circulating CGRP levels are increased in 
external jugular venous blood during a migraine attack (Goadsby et al., 1990), 
others have not been able to reproduce this finding (Tvedskov et al., 2005). This 
has led to continued debate about the circulating levels of CGRP during migraine 
and its involvement in this condition (Tfelt-Hansen and Le, 2009). Intravenous 
administration of CGRP to migraineurs without aura elicits migraine-like 
symptoms (Lassen et al., 2002). Although CGRP application to the dura mater 
does not sensitize dural nociceptors (Levy et al., 2005), transcranial electrical 
stimulation causes nerve terminal release of CGRP and meningeal artery and 
arteriole dilation in a rat model of migraine (Petersen et al., 2004). However, the 
physiological stimulus responsible for the release of CGRP from peripheral nerve 
terminals remains unknown. 
Calcitonin superfamily of peptides 
Because the CGRP receptor is a heterotrimer that includes components 
that are also part of receptors for other members of the calcitonin family, it is 
useful to understand related peptides and receptor components. The calcitonin 
family of peptides includes 6 members: calcitonin (CT), adrenomedullin (AM), 
adrenomedullin-2 (AM2), amylin (AMY), and CGRP, with α-CGRP and β-CGRP 
isoforms (Juaneda et al., 2000; Poyner et al., 2002). Calcitonin is a 32 amino 
acid peptide produced in the thyroid (parafollicular C-cells) that regulates calcium 
(Ca++) homeostasis throughout the body by inhibiting intestinal absorption and 




role in satiety (Erdogan et al., 2006). Adrenomedullin (AM) is a 52 amino acid 
peptide in its active form. Expressed in several tissues, it was first isolated from a 
pheochromocytoma cell line (Kitamura et al., 1998). A potent vasodilator, AM is 
also thought to be involved in angiogenesis and to impart resistance to oxidative 
stress (Kim et al.). Adrenomedullin-2, a 47 amino acid peptide expressed in the 
pituitary and the gastrointestinal tract, displays diverse cardiovascular and 
gastrointestinal effects (Roh et al., 2004). It may play a role in angiogenesis 
(Smith et al., 2009), as well as in placental development and blood pressure 
reduction in pregnancy (Chauhan et al., 2009). Amylin is a 37 amino acid peptide 
produced in the β-cells of the pancreas. Released in a 1:100 ratio with insulin, 
AMY acts synergistically with insulin to maintain glycemic control. Along with 
other members of the calcitonin family, AMY also has a role in bone metabolism 
(Pittner et al., 1994).  
The secondary structures of these peptides are similar, with a single 
disulfide bond forming a six amino acid ring structure near the N-terminus. The 
bodies of these peptides are all comprised of an α-helix with potential amphiphilic 
character. In all cases, the C-termini are amidated (Poyner et al., 2002). 
CGRP structure 
 There are two forms of CGRP; α-CGRP and β-CGRP. Although these 
peptides have similar biological activities, they differ with regard to their sites of 
action and chemical structure. The α-CGRP is a 37 amino acid splice variant of 
the CALCA gene, which contains 6 exons. In neurons, CGRP messenger 




and 6. Alternatively, in thyroid C-cells, calcitonin mRNA is produced by joining 
exons 1through 3 to 4 (Zhou et al., 2007). While CGRP, in general, is distributed 
predominantly in the central and peripheral nervous systems (Amara et al., 1982; 
Poyner et al., 2002), human β-CGRP is more highly localized in the enteric 
nervous system. Human β-CGRP differs by 3 amino acids from human α-CGRP, 
while the rat analogs differ by only one amino acid (Mulderry et al., 1988). 
Interestingly, β-CGRP is encoded by its own gene with high homology to the 
calcitonin gene (Poyner et al., 2002). CGRP shares 50% sequence homology 
with adrenomedullin and some homology with other members of the calcitonin 
superfamily (Arulmani et al., 2004a). Because the N-terminal loop of calcitonin is 
required for receptor activation and signal transduction (Conner et al., 2002), one 
of the first high affinity CGRP receptor antagonists, CGRP8-37, was produced by 
creating a peptide lacking the first seven amino acids of the parent compound 
(Chiba et al., 1989). The amphiphilic α-helix spanning the middle of the peptide is 
critical for receptor binding, with its deletion resulting in a 100-fold decline in 
receptor affinity (Conner et al., 2002). The amidated C-terminal is required for 
maintaining the peptide in the conformation necessary for receptor binding 
(Conner et al., 2002). 
With regard to migraine pathophysiology, α-CGRP is 3 to 6 times more 
concentrated in the sensory nervous systems than β-CGRP (Mulderry et al., 
1988). In addition,, α-CGRP is the major form of this peptide found in the 
trigeminal ganglion (Amara et al., 1985) and cerebral artery vasodilation is 




the remainder of this report, use of the term CGRP refers solely to α-CGRP.  
Cranial location and vascular effects of CGRP 
There is widespread distribution of CGRP positive innervation of cerebral 
vascular structures and CGRP is extensively expressed in nociceptors. The first 
cerebrovascular immuno-positive fibers to be discovered were thought to be of 
trigeminal origin (Uddman et al., 1985). Further work showed the venous 
structures of the dura are more extensively innervated by CGRP positive fibers 
than arterial structures. The superior sagittal sinus (SSS) is the most densely 
innervated of these cerebral vascular structures. In addition to the perivascular 
innervations, some CGRP positive fibers also traverse through the dura obliquely 
from posterolateral to anteromedial. These fibers follow a long straight path and 
are associated primarily with dura mater and not the vasculature. Some end in 
bulbous terminals within the dura and others pass through the dura to form 
arterial associations or to connect to the nerve plexus of the SSS. These dural 
fibers are in close relation to dural mast cells (Keller and Marfurt, 1991). 
Information is lacking about the specific receptor field sizes of the trigeminal 
neurons innervating the dura. Nevertheless, using retrograde tracers, the dural 
fibers were found to originate from the sensory neurons of the trigeminal 
ganglion, with a few originating in the internal carotid and dorsal root ganglia 
(DRG) of the cervical spinal segment (Keller and Marfurt, 1991). 
Other locations and biological functions of CGRP 
Immunoreactive CGRP is found in many regions of the brain. A high 




in the auditory processing regions of the lateral olivochochlear system (Van 
Rossum et al., 1997; Maison et al., 2003). 
Other roles for CGRP possibly include regulation of cholinergic function in 
olfaction and auditory processing (Maison, Adams et al. 2003). This peptide is 
also expressed in the posterior thalamus and is thought to be involved in 
acquisition, consolidation, and retrieval of passively learned information, 
especially that associated with acoustic stimuli (Van Rossum et al., 1997). 
Shown to be involved in feeding and satiety centers (Van Rossum et al., 1997), 
CGRP is present in many parts of the gustatory pathway, including taste bud 
fiber endings and the nucleus of the solitary tract. It is present in structures 
involved in autonomic functioning via the vagus and glossopharyngial nerves, 
and it has been localized in brain regions involved in vision, growth hormone 
secretion, and thermoregulation (Van Rossum et al., 1997).  
It has been proposed that CGRP has a role in the formation, maintenance, 
and functioning of the neuromuscular junction. It is thought to act in concert with 
acetylcholine to enhance the rate of acetylcholine receptor aggregation and to 
potentiate the acetylcholine response in developing myotubes (Buffelli et al., 
2001). With CGRP receptors widely distributed in the cardiovascular system and 
abundantly expressed in conducting system of the heart (Chang et al., 2001), 
CGRP has an ionotrophic effect on heart (Saetrum Opgaard et al., 2000) and 
may have a role in the treatment of congestive heart failure where it has been 
shown to lower blood pressure and increase cardiac output without increasing 




isolated kidney, CGRP increases glomerular filtration rate and sodium excretion 
(Kurtz et al., 1989). This peptide also increases renin production and sodium 
excretion, but not glomerular filtration rate in healthy human volunteers (Kurtz et 
al., 1988; Gnaedinger et al., 1989). 
Transcriptional activation of CGRP gene expression 
 Work on transcriptional activators of CGRP has been performed using 
cultured thyroid C-cells and trigeminal ganglion cells. In these cells, expression of 
the CGRP gene is controlled by a cell-specific, 18 base pair distal enhancer with 
several helix-loop-helix (HLH) binding domains (Lanigan and Russo, 1997). 
Enhancer activation requires an HLH protein heterodimer comprised of upstream 
stimulating factor (USF) 1 and 2 and a cell-specific octamer-binding motif, OB2 
(Lanigan and Russo, 1997). The USF proteins are regulated by the mitogen 
activated protein kinase (MAPK) p38 -mediated phosphorylation (Galibert et al., 
2001), with phosphorylation of the specific MAPK extracellular signal regulated 
kinase (ERK) suggested as a possibility as well (Kutz et al., 2006). It has been 
shown that the CGRP enhancer is stimulated by the MAPK pathway (Durham 
and Russo, 2003), and that USF proteins are activators of the CGRP promoter in 
cultured trigeminal ganglion neurons (Park and Russo, 2008). The CGRP 
promoter contains an element that is cyclic adenosine monophosphate (cAMP) 
and Ras responsive (deBustros et al., 1986). 
Splice determinants of CGRP gene expression 
In neurons, CGRP mRNA is generated by alternate processing of the 




elements and protein factors. Most of these regulators affect the calcitonin-
specific inclusion of exon 4. These include an exonic enhancer element on exon 
4 (Tran et al., 2003), and an intronic enhancer element located downstream of 
exon 4 (Lou et al., 1994). In HeLa cells, Fox1 and Fox2 proteins are key 
silencers of exon 4 expression via the UGCAUG element (Zhou et al., 2007). 
Fox1 and Fox2 and are expressed exclusively in neurons in muscle, heart, and 
brain (Underwood et al., 2005). Although not the only factors involved, Fox 
proteins appear to be critical for determining the splice fate of CGRP pre-mRNA. 
Regulation of CGRP expression and release 
Following an inflammatory insult, nociceptors increase expression of 
CGRP (Devor, 1991a; Ambalavanar et al., 2006a) and medium-sized neurons 
with myelinated axons also begin to express this peptide (Neumann et al., 1996). 
By this process, nociceptors increase their signal strength, and many neurons 
that previously carried only light touch information begin to signal nociception. In 
vitro studies revealed that trigeminal CGRP release is stimulated by potassium 
chloride (KCl), a model of neuronal depolarization (Durham and Russo, 1999), 
capsaisin, through activation of vanilloid receptors (Caterina et al., 1997; Durham 
and Russo, 1999), and by an application of IS, a model neurogenic inflammation 
(Strassman et al., 1996; Durham and Russo, 1999). Studies indicate that 
prolonged elevation of CGRP is facilitated by the nerve growth factor (NGF) and 
MAPK pathways (Durham and Russo, 2003). Sequences near the CGRP gene 
promoter are responsive to various signal transduction pathways, including those 




Latchman, 1995), and activated Ras (Thiagalingam et al., 1996). Additionally, 
because tumor growth factor β (TGF-β) activates USF it has the potential to 
promote CGRP expression (Riccio et al., 1992). Moreover, as CGRP receptor 
activation auto-activates the CGRP promoter through a protein kinase A (PKA) 
dependent mechanism, trigeminal CGRP system could create a self-reinforcing, 
feed-forward amplification of CGRP expression (Zhang et al., 2007b). Release of 
CGRP is inhibited by sumatriptan through a prolonged increase in intracellular 
Ca++ levels (Durham and Russo, 1999), and estrogen increases CGRP mRNA 
and protein expression in the DRG of female rats (Sarajari and Oblinger, 2010). 
Our study focuses on changes in gene expression but those studies described 
above highlight the numerous other important mechanisms that are involved in 
CGRP release and signaling. 
Catabolism of CGRP 
 The actions of CGRP are terminated through cleavage of the peptide by 
ubiquitously expressed neutral endopeptidase (NEP). This 100 kDa type II 
transmembrane glycoprotein cleaves a variety of neuropeptides, including CGRP 
and substance P (Erdos and Skidgel, 1988). This enzyme is widely distributed 
throughout the body where it is, mostly, membrane bound although a soluble 
form has been identified in blood and urine (Erdos and Skidgel, 1988). The NEP 
located in the lung appears to be a major inactivator of substance P, displaying 
88-fold lower activity against CGRP (Katayama et al., 1991). NEP is involved in 
the catabolism of opioid peptides and neutrophil NEP is activated by morphine 





CGRP receptors are formed of three components including a G-protein 
coupled calcitonin-like receptor (CLR), the receptor activity-modifying protein 
(RAMP1) and the receptor component protein (RCP), a coupling protein 
(Arulmani et al., 2004a). The CGRP receptors are divided into two classes, 
CGRP1 and CGRP2, based on the association of RAMP1 with CLR, and in part 
on their sensitivity to the antagonist CGRP8-37 (Dennis et al., 1989; Quirion et al., 
1992). The RAMP1 amplifies the CGRP signal and contributes to sensitization of 
CGRP receptors (Zhang et al., 2007b). 
Calcitonin receptor-like receptor 
 The rat and human calcitonin receptor-like receptors (CLRs) were first 
identified in 1993 (Chang et al., 1993), two years after the CT receptor 
complimentary deoxyribonucleic acid (cDNA) sequence was determined (Lin et 
al., 1991). The receptor is a seven transmembrane domain G-protein coupled 
receptor (GPCR) of the family B or type II variety (Sexton, 1999). The CLR is a 
58 kDa immature protein and 66 kDa protein when glycosylated to its mature 
form (Poyner et al., 2002). Originally considered an orphan receptor, CLR was 
found in transfected HEK cells to produce cAMP accumulation in response to 
CGRP (Aiyar et al., 1996). This work also indicated that the receptor functions 
through a Gsα protein to stimulate adenylyl cyclase. Gene cloning studies 
subsequently identified an accessory protein, RAMP1, was required for CGRP 





Receptor activity modifying proteins 
 The family of receptor activity modifying proteins (RAMPs), RAMP1, 
RAMP2, and RAMP3, act as pharmacological switches, imparting ligand 
specificity (Table 1) when they associate with CPCR (Poyner et al., 2002). These 
single transmembrane domain proteins, which are composed of 148-175 amino 
acids, help determine the selectivity of the calcitonin family receptors. The 
RAMPs possess a large N-terminal extracellular domain and a 9 amino acid C-
terminal intracellular domain (Fitzsimmons et al., 2003). They enable intracellular 
translocation and glycosylation of CLR protein and its insertion into the plasma 
membrane (McLatchie et al., 1998; Foord and Marshall, 1999). When coupled to 
CLR, RAMP1, a 17 kDA protein, produces the CGRP receptor (Banerjee et al., 
2006). 
In contrast to RAMP1, RAMPs 2 and 3 impart preferential receptor 
specificity for AM (McLatchie et al., 1998). These receptors are termed AM1 and 
AM2, respectively (Poyner et al., 2002). Because the AM2 site is activated by 
CGRP at pharmacological concentrations, as with many of the CT family 
receptors it is somewhat promiscuous. The antagonist CGRP8-37 blocks the AM2 
receptor, revealing some pharmacologic characteristics of the previously termed 
CGRP2 while the RAMP/CLR receptor imparts the pharmacological 
characteristics of the previously termed CGRP1 (Hay et al., 2003). While the 
coupling of RAMP with CT produces some specificity for amylin, RAMP1/CT 
(AMY1) is potently activated by α-CGRP while the RAMP3/CT (AMY3) receptor 




has been concluded that the CGRP1 receptor corresponds to the CLR/RAMP1 
complex, and CGRP2 likely corresponds to the AMY1, and less so to the AMY3 
and AM2 receptors. For this reason, it is recommended the term CGRP2 not be 
used any longer (Hay et al., 2008). 
G-protein Coupled 
Receptor 




RAMP2 adrenomedullin (AM) 
receptor, designated AM1 
RAMP3 dual CGRP/AM receptor, 
designated AM2 
Calcitonin receptor (CT) None Calcitonin receptor (CT) 
RAMP1 amylin receptor AMY1 
RAMP2 amylin receptor AMY2 
RAMP3 amylin receptor AMY3 
Table 1. CGRP receptor classification 
CGRP-receptor component protein 
 The CGRP-receptor component protein (RCP) is an important accessory 
protein expressed in CGRP responsive tissues that directly interacts with CLR 
(Evans et al., 2000). The RCP is an intracellular, membrane-associated protein 
(Evans et al., 2000) composed of  146 amino acids with a molecular weight of 17 
kDa (Luebke et al., 1996; Naghashpour et al., 1997). In NIH3T3 cells expressing 
RCP antisense there is a dramatic reduction in CGRP- and AM-stimulated cAMP 
signal responses, although there is no reduction in CGRP binding or receptor 
density. This indicates that RCP is not, as previously thought, involved as a 
chaperone protein for trafficking CLR to the cell membrane (Evans et al., 2000). 
The RCP is thought to work with CLR in coupling the receptor to downstream 




et al., 2002). It has been proposed that RCP is also involved in transcription 
based on the function of its yeast homologue, the C17 subunit of yeast RNA 
polymerase III (Siaut et al., 2003). 
Signal transduction mechanisms 
In general, CGRP receptors signal through Gαs to activate adenylyl 
cyclase and produce cAMP (Wimalawansa, 1996; Poyner et al., 2002). There is 
evidence, however, suggesting that CGRP receptors can also signal through 
Gαq/11 to stimulate phospolipase C (PLC) and thereby activate inositol 1,4,5-
triphosphate (IP3) formation and release of Ca++ from the endoplasmic reticulum 
(Drissi et al., 1998). Changes in G-protein coupling is a potential mechanism to 
central sensitization (Winter and McCarson, 2005). 
The MAPK pathway is also activated through stimulation of the CGRP 
receptor (Schaeffer et al., 2003; Vause and Durham, 2009). In smooth muscle, 
CGRP increases the activity of ERK1/2 and p38 MAPK (Schaeffer et al., 2003) 
and in DRG neurons ERK1/2 is activated in response to CGRP (Anderson and 
Seybold, 2004). Stimulation of these pathways is known to increase expression 
of inflammatory mediators (Kaminska, 2005) and to play a role in initiating and 
perpetuating peripheral sensitization (Ji, 2004).  
 The vasodilatory effects of CGRP are mediated through both endothelial- 
dependent and -independent mechanisms (Wimalawansa, 1996). With respect to 
the endothelial-dependent mechanism, activated CGRP receptors in endothelial 
cells activate endothelial nitric oxide synthase (eNOS). This stimulates the 




increases cyclic guanosine monophosphate (cGMP) which causes relaxation of 
smooth muscle (Muff et al., 2001; de Hoon et al., 2003). The endothelial-
independent mechanism is the process thought to be responsible for vasodilation 
in human cranial arteries. In this process, CGRP reaches the perivascular 
smooth muscle by diffusion or release from local nerve terminals. It binds to its 
receptor and activates adenylyl cyclase, increasing intracellular cAMP, leading to 
vasodilation. In a separate endothelial-independent mechanism, CGRP is able to 
phosphorylate and open ATP-senstive potassium channels (KATP) channels, 
thereby hyperpolarizing the cell and causing vascular relaxation (Wimalawansa, 
1996; Van Rossum et al., 1997; Gozalov et al., 2008). 
Regulation of CGRP receptor expression 
 Very little is known about what influences the expression of CGRP 
receptor components. While it has been reported that in vitro stimulation of 
CGRP receptors with 1 μM CGRP does not change expression of CLR, RAMP1, 
RAMP2 or RAMP3 mRNA in osteoclasts (Granholm et al., 2008), in vivo data are 
lacking and other cell systems remain to be examined.  
CGRP receptor distribution 
CGRP receptors are found in a variety of tissues including those in the 
central and peripheral nervous systems (Arulmani et al., 2004a), as well as in the 
gastrointestinal, cardiovascular, respiratory, endocrine, and musculoskeletal 
systems (Hagner et al., 2002; Rossi et al., 2003). There are high levels of CGRP 
receptor expression in heart and blood vessel tissue (Wimalawansa, 1996), with 




receptors have also be detected in coronary arteries, veins, arterioles, heart 
valves, and endocardium (Wimalawansa, 1996), helping to explain the 
chronotropic and ionotropic effects of this peptide (Saetrum Opgaard et al., 2000; 
Poyner et al., 2002). In DRG neurons, CGRP receptors are co-expressed with 
receptors for other neurotransmitters, such as substance P, vasoactive intestinal 
peptide (VIP), neuropeptide Y, and norepinephrine (Van Rossum et al., 1997), 
and in autonomic neural tissue they are co-expressed with tachykinins and 
substance P (Ursell et al., 1991). Co-localization of CGRP and CGRP receptor 
components in primary sensory neurons and motor neurons suggests this 
peptide has autocrine or paracrine functions in these systems (Ma et al., 2003).  
CGRP receptor expression in migraine relevant tissues  
The relevance of these proteins to migraine is indicated by the fact that 
CLR, RAMP1, and RCP are expressed in human cerebral blood vessels (Moreno 
et al., 2002), dura mater, dural mast cells, trigeminal ganglion and presynaptic 
nerve terminals in the spinal trigeminal nucleus (Lennerz et al., 2008). They are 
also found in peripheral and central nervous system neurons and glial cells (Levy 
et al., 2004), Schwann cells (Lennerz et al., 2008) and trigeminal ganglia glial 
cells (Li et al., 2008). It is notable, however, that CGRP receptors do not appear 
to be present on trigeminal nerve endings (Lennerz et al., 2008).  
Basis for sex differences in migraine 
Migraines are 3 times more prevalent in women and the severity of 
migraine pain often varies with the menstrual cycle, peaking around the time of 




condition, temporomandibular disorder, has also been shown to vary with the 
menstrual cycle, indicating higher levels of trigeminal pain when estrogen drops 
to its lowest levels in the perimenstrual periods (LeResche et al., 2003). 
Moreover, it is notable that CGRP receptor protein expression and the effects of 
CGRP on myometrial contraction change with the estrous cycle in mice 
(Naghashpour and Dahl, 2000). Receptive field sizes of neurons in the spinal 
trigeminal nucleus are larger when estrogen levels are high (Bereiter and Barker, 
1975). Estrogen increases excitability of trigeminal nociceptors (Flake et al., 
2005) as well as ERK activation and orofacial allodynia in a model of 
inflammatory pain (Liverman et al., 2009a). These studies indicate that estrogen 
regulates the excitability of trigeminal neurons and increases responses to 
inflammation. However, there have been few studies addressing the sex 
differences in peripheral or central sensitization in migraine models. 
Published studies in the Berman laboratory have demonstrated that 
estrogen amplifies the behavioral response to inflammatory pain in a 
temporomandibular model. These investigators have also found that two types of 
estrogen receptors are present in likely nociceptors, and that estrogen stimulates 
the intracellular MAPK signaling pathway ERK, which is also activated during 
sensitization in chronic pain conditions (Puri et al., 2005; Puri et al., 2006). 
Migraine pharmacotherapy 
Because of the data indicating that migraine results from a dysfunction of 
the vascular system, pharmacologic therapy has focused on the use of 




this approach. However, because of its diverse pharmacodynamic actions that 
contribute to adverse effects, ergotamine is not an ideal therapy for the relief of 
migraine symptoms (Tfelt-Hansen, Saxena et al., 2000; Tfelt-Hansen and 
Koehler, 2008).  
Analgesics 
Many studies have demonstrated that non-steroidal anti-inflammatory 
drugs (NSAIDs) and opioids are effective in the acute management of migraine. 
Efficacy has been demonstrated for acetylsalicylic acid in doses up to 1000 mg 
(Tfelt-Hansen and Olesen, 1984), ibuprofen at 200-800 mg (Diener et al., 2004), 
diclofenac at 50-100 mg (Linde, 2006), and acetaminophen at 1000 mg (Peatfield 
et al., 1983). In addition, opioids such as propoxyphene (Hakkarainen et al., 
1978) and codeine (Somerville, 1976) are known to be effective treatments as 
well. Therefore, analgesics are considered first line drugs for the acute treatment 
of migraine and are often administered in combination with antiemetics such as 
metoclopramide or domperidone to treat the nausea that may accompany this 
condition. The antiemetics may also reverse some of the gastric stasis that 
results from sympathetic activation due to migraine and thereby aid in drug 
absorption (Welch, 1993).  
Ergot alkaloids 
Targeted therapies for treating migraine were not available until the 20th 
century. In 1906, Dale showed that an extract of ergotamine tartrate inhibits the 
pressor effect of sympathetic stimulation, and, in 1918, Stoll isolated and purified 




in sympathetic activity. As ergotamine was shown to have sympatholytic effects, 
it was a logical choice as a possible therapy for this condition and, in 1925, 
Rothlin proposed that it be used to treat migraine (Rothlin, 1955; Stoll, 1955). His 
recommendation appeared strengthened by positive results of a clinical trial 
conducted that year (Tfelt-Hansen and Koehler, 2008).  
In 1938, Wolff and Graham proposed that the effectiveness of ergotamine 
in treating migraine is because the drug constricts cranial vasculature. This group 
reported that the temporal artery pulse pressure amplitude was decreased with 
administration of ergotamine (Graham and Wolff, 1938; Wolff, 1955; Tfelt-
Hansen and Koehler, 2008). This study provided the first direct evidence in 
support of the vascular theory of migraine and led to the hypothesis that the 
condition is the result of cranial vasodilation. This finding led to the refinement of 
the treatment options for migraine. Synthesized in 1943, dihydroergotamine 
(DHE) was predicted to be more effective than ergotamine because it is more 
selective for α-adernergoceptors. While clinical trials revealed that DHE is slightly 
less potent than ergotamine in the acute treatment of migraine, it was found it 
could also be used prophylactically to reduce the number and severity of 
migraine attacks (Rothlin, 1955; Tfelt-Hansen and Koehler, 2008). 
Although the ergot alkaloids were the recommended class of drugs for 
acute therapy, there are few placebo controlled, randomized clinical trials 
attesting to their efficacy. It is now appreciated that the ergot alkaloids probably 
act primarily as 5-HT1 receptor agonists in treating migraine, although with less 




constriction. Regardless of the route of administration, ergotamine tartrate is 
effective in less than 50% of migraine patients (Welch, 1993). When given 
parenterally, even when together with an antiemetic, DHE is less efficacious than 
sumatriptan but as effective as opioids (Colman et al., 2005). Both ergotamine 
and DHE treatment are associated with numerous adverse effects, including 
drug-overuse headaches that occur quickly and often at low doses (Linde, 2006). 
Triptans 
More selective 5-HT receptor agonists for the treatment of migraine 
headache, the triptans, were developed in the late 1980’s. The first member of 
this class developed for human use was sumatriptan (Feniuk et al., 1991; 
Humphrey et al., 1991). The triptans are thought to be superior to the ergot 
alkaloids in the treatment of migraine symptoms because of their greater 
selectivity for cerebral vascular 5-HT1B receptors and for the 5-HT1D receptors in 
trigeminal neurons. At therapeutic doses the triptans cause constriction of the 
cerebral vasculature, and in addition, they inhibit trigeminal function peripherally 
by reducing CGRP release and centrally by blocking action potentials in the 
spinal trigeminal nucleus (Tfelt-Hansen et al., 2000).  
Triptans, the best studied migraine drugs, are selective for the 5HT1D 
receptor subtype located on the peripheral terminal of trigeminal neurons of 
vascular and meningeal structures and the 5HT1B receptor subtype found on the 
smooth muscle and endothelium of cerebral arteries that mediate 
vasoconstriction (Nilsson et al., 1999). The first drug of this class, Introduced for 




migraine since then. Comparative trials of sumatriptan versus other triptans such 
as rizatriptan, zolmitriptan, and naratriptan have shown small, but statistically 
significant, differences in efficacy. The clinical relevance of these differences is 
still being debated (Saxena and Tfelt-Hansen, 2000). Suggested doses of 
sumatriptan are 6 mg and 100 mg for subcutaneous and oral administration, 
respectively. Triptans are slightly more efficacious than most analgesic/anti-
emetic combinations and are effective in 60% of patients whose migraines are 
refractory to NSAIDs. The triptans are less effective when administered during 
the aura phase of the migraine, with administration during the headache phase 
only recommended (Linde, 2006). Due to its short elimination half-life (2 hours), 
headache can return within 24 hours but is typically relieved by a second dose of 
sumatriptan (Welch, 1993). Because triptans are vasoconstrictors, they are 
contraindicated in those with significant cardiovascular disease, unmanaged 
hypertension, and for certain types of migraine, such as hemiplegic and basilar-
type migraine (Dodick et al., 2004). Vasocontractile responses to triptans 
correlates with plasma concentrations in cerebral, but not coronary (Edvinsson et 
al., 2005). Each one of these approaches has had limited to moderate effects in 
treatment of migraine. The NSAIDs are less effective than other available 
therapies. Ergot alkaloids and triptans while more effective cannot be prescribed 
in patients with hypertension and cardiovascular risk factors for stroke. This has 
led to development of a new class of drugs, the CGRP antagonists. 
CGRP antagonists 




The first of these, olcegepant (Figure 2), was developed by Boehringer Ingelheim 
(Doods, 2001). In animal models and isolated human cerebral arteries, 
olcegepant blocks the cerebral vascular effects of CGRP and trigeminal 
stimulation (Doods et al., 2000; Kapoor et al., 2003a; Kapoor et al., 2003b; 
Petersen et al., 2004), while having no effect in the absence of CGRP exposure 
(Kapoor et al., 2003b; Arulmani et al., 2004b). Initial clinical trials revealed an 
acceptable safety profile (Petersen et al., 2005a) and efficacy in preventing 
CGRP induced headache and vascular changes in healthy volunteers (Petersen 
et al., 2005b). A phase II clinical trial demonstrated the antimigraine effectiveness 
of olcegepant following intravenous administration, with the optimal dose being 
2.5mg (Olesen et al., 2004).  
 
 
Figure 2. Olcegepant 
Because olcegepant is not orally active, efforts were undertaken to 
develop CGRP antagonists that are bioavailable by this route (Williams et al., 
2006). These resulted in the identification of telcagepant (Figure 3) (Paone et al., 
2007). In vitro testing revealed that telcagepant binds with high affinity to CGRP 




transfected cells expressing human CGRP receptor, has high selectivity for 
CLR/RAMP1 receptors versus other calcitonin family receptors, and displays a 
1500-fold higher affinity for human CGRP receptors over dog and rat receptors 
(Salvatore et al., 2008). Telcagepant inhibits endogenous CGRP-induced and 
transient receptor potential vanilloid (TRPV) 1 receptor facilitated cutaneous 
vasodilation in the rhesus forearm in a concentration-dependent manner 
(Salvatore et al., 2008). A phase II, dose-ranging study showed that 300 mg of 
telcagepant displays an efficacy similar to a 10 mg dose of rizatriptan (Ho et al., 
2008b). Approximately 69% of both groups reported pain relief 2 hours following 
treatment. The most common adverse events reported following administration of 
telcagepant were nausea, dizziness, and somnolence (Ho et al., 2008b). In a 
phase III trial of telcagepant, a 300 mg dose of telcagepant is as effective for the 
acute treatment of migraine as the most effective (5 mg) dose of zolmitriptan and 
more effective than placebo (Ho et al., 2008a). In this study there were fewer 
side effects reported by those taking telcagepant than by those treated with 
zolmitriptan. Importantly, it does not appear that CGRP antagonists have direct 
vasoconstrictor properties (Ho et al., 2008a), as suggested by a study showing 
that treatment with 500 mg of telcagepant does not block the vasodilatory effects 
of sublingual glyceryl trinitrate (GTN) in healthy male volunteers (Van Der 
Schueren et al., 2009). This suggests that telcagepant can be employed for the 
treatment of migraine in those with high cardiac risk profiles. 
It was recently reported that liver transaminases are elevated following 




schedule used in this study differs from that required for acute treatment of 
migraine, the results have slowed the clinical development of this compound as 
its potential toxicity is reassessed (Merck, 2009). 
 
 
Figure 3. Telcagepant 
MK-3207 
Other CGRP receptor antagonists, such as MK-3207 (Figure 4) have been 
developed that display a higher affinity than telcagepant for the CGRP receptor 
(Salvatore et al., 2010). For MK-3207, the Ki for inhibition of 125I-hCGRP binding 
to membranes taken from stably transfected HEK293 cells expressing 
CLR/RAMP1 receptors is 21 pM in comparison to 770 pM for telcagepant, and 
the MK-3207 IC50 for inhibiting CGRP-induced cAMP formation is 0.12 nM as 
compared to 2.2 nM for telcagepant (Salvatore et al., 2010). This agent also 
demonstrates good oral bioavalability in rhesus monkeys, dogs, and rodents. In a 
capsaicin-induced dermal vasodilation model in rhesus monkeys, MK-3207 is 
reported to be approximately 100-fold more potent than telcagepant (Salvatore et 




MK-8825, displays a similar preclinical profile to MK-3207 (Bell et al., 2010). 
  
 
Figure 4. MK-3207 
Prophylactic therapy 
Prophylactic therapy is employed for only the most severe cases of 
migraine. Many of the agents used for this purpose have potentially serious 
adverse effects and can interact with other drugs. Currently, the drugs of choice 
for prophylactic use are the beta-adrenoceptor antagonists propranolol and 
metoprolol, the calcium channel blocker flunarizine, and the anticonvulsants 
valproic acid and topiramate (Linde, 2006). Whereas, estrogen is indicated for 
prophylactic use in menstrual migraine. In some cases non-pharmacological 
approaches, such as relaxation and meditation, have also proven effective as 
prophylactic treatments for migraine (Linde, 2006). 
Overall, treatment of migraine even today is empirically driven, reflecting 
the lack of understanding about the underlying pathophysiology. In the coming 
years it is anticipated that new findings about the underlying physiological 




prophylactic therapies and a more rational approach to it treatment. The present 
study was undertaken to obtain some of the data needed to attain these 
objectives. 
Models of migraine pain 
The IHS-2 criteria for migraine include at least 5 headache attacks lasting 
4-72 hours that have at least two of the following characteristics: unilateral, 
pulsating, moderate or severe pain intensity aggravated by routine physical 
activity, and at least one of these characteristics: nausea and/or vomiting, 
photophobia and phonophobia. Allodynia occurs when normally innocuous 
stimuli are able to induce pain, and hyperalgesia is an increased sensitivity to a 
stimulus that was previously painful. The presence of allodynia is associated with 
more severe headaches (Burstein et al., 2004), with many migraineurs 
experiencing thermal and mechanical allodynia in regions innervated by the 
trigeminal nerve (Burstein et al., 2000b; Goadsby, 2005; LoPinto et al., 2006). 
While many of these IHS targeted migraine behaviors can be examined in 
rodents most animal models of trigeminal pain were designed to study 
temporomandibular disorder. Some have used neuropathic pain models to 
examine conditions associated with trigeminal pain. Nerve ligation, a method for 
inducing neuropathic pain, has been employed in studying rodent behavior in the 
presence of pain. For example, an increased mechanical sensitivity has been 
quantified after ligation of the infraorbital nerve (Vos et al., 1994). 
Common approaches for the study of temporomandibular disorder involve 




third branch of the trigeminal nerve followed by measurement of various 
behavioral endpoints. Examples of this approach include injection of Complete 
Freund’s Adjuvant (CFA) into the temporomandibular joint or masseter muscle to 
cause facial allodynia (Ambalavanar et al., 2006b) and altered feeding behavior 
(Kerins, 2005). Formalin has been injected into the same regions followed by an 
analysis of facial grooming (Clavelou et al., 1995), hyperalgesia, and allodynia 
(Imbe et al., 2001). Grooming has also been measured after injection of 
capsaicin into the vibrissa (Pelissier et al., 2002). A newer approach, and one 
that appears more relevant for the study of migraine, is production of allodynia by 
application of an IS to the dura of conscious rats 3 times/week for 4 weeks 
(Oshinsky and Gomonchareonsiri, 2007). 
Behavioral assays 
The difficulty of creating a migraine behavioral model was aptly 
summarized by Harold Wolff in 1938: 
Pain is certainly the commonest complaint with which the physician must 
deal and headache probably the commonest pain. Pain must be studied in 
conscious human beings. Since it is a sensory experience it must be 
reported by man. Thus, when the effects of noxious stimulation are 
studied in animals by observation of skeletal muscle responses, these 
cannot be considered as responses to pain because animals cannot give 
subjective report of their sensation. In animals, one studies not pain, but 
reaction to noxious stimulation (Graham and Wolff, 1938). 




recording or c-fos immunohistochemistry in the spinal trigeminal nucleus as 
surrogate measures of trigeminal pain (Bergerot et al., 2006). Because in the 
present study, behavioral assays are used as measures of trigeminal pain, it is 
important to review the behavioral measures used in the past for such studies...  
Behavioral assays: trigeminal pain models 
For years, behavioral measures of trigeminal pain have included facial 
allodynia and hyperalgesia, both thermal and mechanical, facial grooming, and 
altered feeding behavior. In the studies described here we used several of the 
behavioral assays described below. 
Mechanical facial allodynia and hyperalgesia 
Testing mechanically for facial allodynia and hyperalgesia is one of the 
most common behavioral tests used in models of trigeminal pain. In these 
assays, rats are habituated to stand still either by restraining them by hand, 
restraining them in an enclosure, or using operant conditioning to drink 
sweetened water to ensure immobilization (Ambalavanar et al., 2006b; Oshinsky 
and Gomonchareonsiri, 2007; Liverman et al., 2009a). Testing of the three 
different branches of the trigeminal innervation most frequently involves 
mechanically stimulating the masseter, whiskerpad, and periorbital regions of the 
face with standard force von Frey filaments. A variable force transducer can be 
coupled to the filament to measure allodynia. This model has shown that multiple 
infusions of IS on the dura induce an interictal allodynia that lasts for longer than 
3 weeks after the final infusion. In this model, increased allodynia and increased 




are further potentiated by IS-induced chronic trigeminal hypersensitivity 
(Oshinsky and Gomonchareonsiri, 2007). Another study showed that facial 
allodynia peaks 3 hours following application of IS to the dura and is reversed by 
administration of sumatriptan, naproxen, or the CGPR antagonist CGRP8-37, but 
not affected administration of a neurokinin-1 (NK-1) antagonist (Edelmayer et al., 
2009). Similarly, induction of mechanical facial allodynia is observed following 
application of either human immunodeficiency virus (HIV) glycoprotein gp120 or 
an IS (Wieseler et al., 2009). Another model utilizes a focused air current 
directed at the animal’s head to elicit ultrasonic vocalization (USV). Rats 
receiving intracerebroventricular lipopolysaccharide displayed an increase in 
USV in comparison to naïve animals. The relevance of this model to migraine is 
indicated by the fact that the increased USV is abolished by administration of 
morphine, ketorolac, zolmiptriptan, sumatriptan, dihydorergotamine, or CGRP8-37 
(Martino and Perkins, 2008). 
Thermal facial allodynia and hyperalgesia 
Others have measured thermal hyperalgesia in the trigeminal territories of 
rats. The regions to be thermally stimulated are shaved to ensure contact 
between the thermal source and the skin. Similar to mechanical testing, the rat is 
trained to hold its head still by drinking water allowing the skin to come into 
contact with the thermal source. As the rat accesses the reward, the temperature 
of the thermal stimulus is increased. The sensitivity of the animal is measured by 
recording the temperature at which the rat withdraws its head from the water 




Hind paw mechanical hyperalgesia models 
In order to measure hind paw mechanical hyperalgesia, the rodent is 
placed on a mesh floor and a von Frey filament or similar object is used to prod 
the foot pad from underneath. The normal response to this stimulus is a 
nocifensive withdrawal reflex and a relatively quick return of the foot to the floor. 
Increased sensitivity to this mechanical stimulus is indicated by a more 
pronounced foot withdrawal and a longer period of withdrawal. In some cases a 
hyperalgesic animal will attend to the stimulated foot by licking it. The withdrawal 
time can be measured with a stopwatch. This procedure, combined with a 
measure of mechanical allodynia, are together referred to as the up-down 
method (Chaplan et al., 1994).  
For the up-down method, mechanical allodynia is tested using von Frey 
filaments. These filaments are of differing diameters, each of which is designed 
to exert a standardized force when pressed against the skin to the point of 
bending. The force required to elicit a response is then recorded as the threshold 
for mechanical allodynia (Chaplan et al., 1994). This procedure has been used to 
demonstrate that hind paw allodynia peaks at 3 hours following application of IS 
to the dura and, as with mechanical facial allodynia, this mechanical hind paw 
allodynia is reversed by administration of sumatriptan, naproxen, or the CGRP 
receptor antagonist, CGRP8-37, but not affected by administration of the NK-1 
receptor antagonist (Edelmayer et al., 2009).  
The Randall-Selitto method is another common procedure for measuring 




apparatus is used to move a screw against a specific location on the footpad. 
The pressure is slowly increased, with that required to stimulate a foot withdrawal 
or vocalization recorded as the pain threshold (Randall and Selitto, 1957). 
Facial grooming 
Facial grooming is also used to assess trigeminal nerve sensitization. 
After injection of capsaicin into the whisker pad, the rat is observed and the pain 
score measured by the number of seconds spent grooming the injection site with 
the ipsilateral fore- or hind paw within a 42 minute period (Clavelou et al., 1995; 
Pelissier et al., 2002) 
Altered feeding behavior 
Other behavioral measurements of pain include changes in meal duration, 
meal size, and number of meals (Kerins et al., 2004; Kerins et al., 2005).Notably, 
meal duration appears to be the best indicator of temporomandibular pain, being 
significantly increased for 24 to 48 hours after CFA injection into the 
temporomandibular joint (Kerins et al., 2005). 
Photophobia 
Few have attempted to test for photophobia. In principle, rats and mice are 
normally photophobic because they avoid well illuminated open spaces at all 
times. There is a report of a photophobic test using a strain of mice that displays 
photophobicity when placed in a divided light/dark enclosure (Thiels, 2008). A 
study of transgenic mice that over-express human RAMP1 protein in peripheral 




defined by an increased time spent in the dark chamber of a 1000 lux light-dark 
box. The light-aversive behavior was exacerbated by the intracerebroventricular 
administration of CGRP, and blocked by co-administration of olcegepant, a 
CGRP receptor antagonist (Recober et al.; Recober et al., 2009). 
Behavioral assays in other pain models 
 Behavior has been an endpoint in a variety of animal pain models. It is 
possible that some of these might be appropriate for establishing preclinical 
models of migraine pain.  
Thermal sensory models 
An approach for measuring thermal hyperalgesia of the footpad is to place 
a light below a glass bottomed enclosure. The light is positioned below the 
resting footpad of an unrestrained rat and then turned on. As the light source 
begins to heat the glass and the footpad, the latency for withdrawal of the foot is 
measured by a sensor coupled to a timer. This assay displays better sensitivity in 
a carrageenan-induced inflammatory model then the Randall-Selitto mechanical 
sensitivity assay (Hargreaves et al., 1988). 
Cold allodynia can also be used to study a decrease in pain threshold. In 
one assay procedure, the animal is placed on a cold metal plate at 4° C for 20 
minutes. Allodynia is quantified by counting the number of nocifensive withdrawal 
reflexes observed when the affected foot pad touches the floor. This value is 
compared with the number of nocifensive withdrawals recorded when the animal 
is placed on a metal floor warmed to 30° C (Choi et al., 1994).  




typically performed with rats and utilizes on the wire mesh floor used for 
mechanical testing. As it evaporates, the acetone causes a cooling sensation 
within 1-2 seconds. Normal animals ignore this sensation, but sensitized subjects 
display strong nocifensive withdrawal responses that can be readily quantified by 
counting. 
Actimetry 
Actimetry is a method for measuring gross animal behavior. For the test, 
the animal is placed in an enclosed area where high sensitivity force transducers 
are coupled to the four corners of a rigid, low-mass floor to monitor and track 
locomotor activity. Software processes the force-location data and provides a 
detailed analysis of locomotor behavior. Additional analysis can be employed to 
yield information about ambulation, tremors, and certain physiological 
parameters. Actimeter measurements have been used to describe animal 
behavior following manipulation of brain dopaminergic systems (Bonatz et al., 
1987) and to measure pharmacologically-induced behavioral changes 
(Kuczenski and Segal, 1999; Chen et al., 2003; Fowler et al., 2003; Fowler et al., 











Migraine is among the most common neurological diseases, occurring in 
12% of the population (Stovner et al., 2007; Bigal and Lipton, 2009) and there is 
evidence that the condition is under-diagnosed (Buse et al., 2009). The true 
societal impact is compounded by the debilitation and losses in productivity that 
accompany the disorder (Buse et al., 2009). It is 3 times more prevalent in 
females than males (Bigal and Lipton, 2009). The pathophysiology of migraine is 
poorly understood, in part because of the lack of preclinical models of headache. 
In addition, the reason for the female predominance is not understood 
(Rasmussen, 1993; Bigal and Lipton, 2009). Because there is no objective test 
for the condition, migraine is diagnosed using clinical criteria established by the 
IHS. These are based on presenting behavioral signs and symptoms, including 
duration and intensity of pain, pulsating and unilateral nature of pain, and 
avoidance of routine physical activity. 
Previous attempts to model and study migraine have employed 
electrophysiological techniques, yielding important information about the 
neuronal sensitization that appears to underlie the disorder (Burstein et al., 1998; 
Jakubowski et al., 2007). Others have focused on studying related trigeminal 
pain conditions such as temporomandibular disorder, which have symptoms that 
are well suited for study in animal behavioral tests (Clavelou et al., 1995; Kerins 
et al., 2004; Ambalavanar et al., 2006b; Takeda et al., 2007; Liverman et al., 
2009a). However, none of these approaches include the behaviors specifically 
associated with the IHS criteria for diagnosing migraine in humans.  




important in migraine pathophysiology. Because CGRP is a vasoactive 
neuropeptide, it could contribute to the vasodilatory component of migraine 
(McCulloch et al., 1986). Moreover, it has been shown that CGRP levels in 
plasma are increased following activation of the trigeminal system and CGRP is 
present in nociceptors including those in the trigeminal ganglion that innervate 
cerebral vasculature (Goadsby et al., 1988; Moskowitz and Macfarlane, 1993; 
Ambalavanar et al., 2006a). The overall hypothesis of this study is that dural 
inflammation will induce allodynia, reduced locomotor activity, and 
increase CGRP and CGRP receptor gene expression in the trigeminal 
nervous system in male and female rats. Changes in behavior and gene 
expression will be more pronounced in females. 
The following dissertation is organized in a format based on prepared 
publications such that each specific aim contains an abstract preceding each 
report of results and discussion. In some cases there is repetition of background 
information first presented in the general introduction section within the aims 
section. This organization enables each aim to be read and understood 
individually.  
Based on previous findings, this dissertation project has the following aims: 
1. To test the hypothesis that locomotor activity and mechanical facial 
allodynia are modulated in a sex-dependent manner in response to 
inflammation of the dura mater in a rat model of migraine. 
Earlier studies indicate that application of IS to the dura mater causes 




Jakubowski, 2004; Jakubowski et al., 2007) and mechanical periorbital allodynia. 
Mechanical periorbital allodynia was demonstrated acutely following a single 
application (Edelmayer et al., 2009; Wieseler et al., 2009) and interictally 
following chronic application of IS (Oshinsky and Gomonchareonsiri, 2007). In 
the present study, a new behavioral assay is developed that measures changes 
in routine activity, one of the IHS criteria for migraine, using actimetry to measure 
distance traveled and bouts of low mobility during application of IS to freely-
moving rats. An established procedure for measuring periorbital allodynia is 
coupled with the locomotor assay to obtain data from both male and female rats 
receiving two different volumes of IS or vehicle. The data are analyzed to 
investigate whether there are sex differences in any IS-induced changes in 





2. To test the hypothesis that expression of genes encoding for 
calcitonin gene-related peptide and related receptor components are 
modulated in a sex-dependent manner in response to inflammation 
of dura mater in a rat model of migraine. 
To address this issue, sex-dependent variations in gene expression of 
CGRP and its associated receptors, CLR, RAMP1, and RCP in the trigeminal 
pathway are examined following application of an IS to the rat dura. 
Others have shown that intravenous administration of CGRP to 
migraineurs without aura elicit migraine-like symptoms as defined by IHS criteria 
(Lassen et al., 2002). However, no one has examined whether there are sex-
related differences in gene expression of CGRP and CGRP receptor or how 
expression of these genes is modulated in a model of neurogenic inflammation. 
In this study the gene expression of CGRP and CGRP receptors is evaluated 
using quantitative real-time polymerase chain reaction and an attempt made to 
















Animal care and use procedures were approved by and conducted 
according to University of Kansas Medical Center Institutional Animal Care and 
Use Committee and Institute of Laboratory Animal Research guidelines. Ten 
week old, sexually mature Sprague-Dawley rats were purchased from Harlan 
Sprague-Dawley Inc. (Indianapolis, IN). The animals were housed in the Kansas 
University Medical Center Laboratory Animal Resources Facility in plastic cages 
and provided water and food ad libitum. The animals were all subject to a 12 
hour light-dark cycle. The rats were divided into groups based on sex, application 
of IS or control vehicle, and volume of application. All behavioral experiments 
were conducted between 9:00 and 14:00 h in a dedicated, temperature-
controlled room. 
Cannula implantation 
The cannula for dural delivery of the IS or vehicle was a Plastics One 
(Roanoke, VA) product made of biocompatible material implanted into the skull 
under isoflurane anesthesia (3.5% isoflurane for induction and 2.7% for 
maintenance in 4% oxygen). During surgery, sterile ophthalmic ointment was 
used to protect the rat’s eyes and absence of a corneal reflex confirmed the level 
of anesthesia. The animal was placed in a stereotactic apparatus, immobilized at 
the external auditory meati and incisors, and the cannula placed on the right side 




occipital lobe to model unilateral migraine. The dura mater was exposed by first 
thinning a 1 mm diameter region of the skull using a burr drill to remove the outer 
layer, taking care to irrigate the skull with sterile saline to prevent heating. A 
McCall currette was used to carefully remove the inner layer of bone while 
leaving the underlying dura intact. Sterile petrolatum was placed over the intact 
dura to prevent dural fixation to the cannula and calvarium. Single rostral and 
caudal drill holes were placed 3 mm from the center of the cannula, and stainless 
steel screws attached to the skull to provide anchors for the dental cement 
(Ortho-Jet, Lang Dental Mfg. Co., Inc., Wheeling IL) used to provide stability to 
the cannula. An internal obturator was placed within the cannula to maintain 
patency. The scalp was folded over the base of the cannula and sutured using #4 
sterile silk. Following recovery from the isoflurane anesthesia, the animal was 
administered buprinorphine (0.05 mg/kg in 1 mL normal saline) by intraperitoneal 
injection for analgesia, and transferred to a clean cage with an external heat 
source. Breathing and movement were observed until the animal was fully awake 
and mobile. The rat was then returned to its home cage. Following implantation, 
the cannula and obturator cap projected less than one centimeter from the right 
side top of the head. Closure of the skin around the cannula was confirmed prior 
to behavioral testing. A preliminary study showed no behavioral differences 
between rats with cannulas implanted and non-surgical control animals (data not 
shown). In the rare case (2/43) where animals became ill following surgery, they 
were removed from the study. All animals were monitored regularly for health 





The vehicle control groups received regular application to the dura of 10 or 
20 μL of pyrogen-free phosphate buffered saline (PBS) adjusted to a pH of 7.4. 
Groups selected for the inflammatory stimulus received regular application to the 
dura of 10 or 20 μL of IS consisting of 1 mM histamine, 1 mM 5-HT, 1 mM 
bradykinin, and 0.1 mM PGE2, in PBS at a pH of 5.5 (Table 2). For application to 
the dura of IS or vehicle, the obturator cap of the cannula was removed and an 
internal delivery cannula inserted and connected to PE50 tubing attached to an 
infusion pump (Cole Parmer) that delivered vehicle or IS at a rate of 2 or 4 
μL/min over 5 min (Burstein and Jakubowski, 2004; Oshinsky and 
Gomonchareonsiri, 2007). Following application of IS or vehicle and locomotor 
testing, the internal delivery cannula was removed and replaced with the 












Naïve control Male - - - mRNA 
Female - - - mRNA 
Vehicle control Male PBS 10 μL Locomotor, 
Allodynia 
mRNA 
20 μL Locomotor, 
Allodynia 
mRNA 
Female  PBS 10 μL Locomotor, 
Allodynia 
mRNA 







Male IS 10 μL Locomotor, 
Allodynia 
mRNA 
20 μL Locomotor, 
Allodynia 
mRNA 
Female IS 10 μL Locomotor, 
Allodynia,  
mRNA 





Table 2. Treatment groups 
Timeline 
Prior to surgery the rats were trained for 10 days in the allodynia task, and 
presurgical baseline behavioral responses measured for all tasks one day prior to 
surgery. Rats were allowed to recover for 7 days following surgery before 
resuming behavioral testing, a time when preliminary studies revealed the 
behavioral responses had returned to presurgical baseline values. Postsurgical 
behavioral measurements were obtained two days before delivering the first 
application of vehicle or IS. 




application of IS to the dura, when cutaneous allodynia responses are most 
pronounced (Oshinsky and Gomonchareonsiri, 2007). Because the temporal 
relationship between inflammation of the dura and onset of headache is not well 
understood, animals were tested during application of IS and during a second 
period 5 minutes later to determine the duration of the effects. The first five 
minutes (during IS application) was termed the “onset phase”, while the 10-15 
minute time period after IS application was termed the “persistence phase”. 
Behavioral data were collected after application of IS on every 3rd day for a 7 
total applications. A final behavioral data point was taken 48 hours after the last 
application of IS. Locomotor and facial allodynia results were recorded for 
comparison with other studies, most of which focused on the measurement of 
interictal time points (Oshinsky and Gomonchareonsiri, 2007; Edelmayer et al., 
2009). The post-surgical baseline interictal data were subtracted from the Day 8 
interictal results to calculate changes occurring over the 2.5 weeks of the 
experiment. For all behavioral testing, rats were coded and experimenters blind 
to treatment.  
 Aim 1 methods 
Mechanical allodynia test 
An operant conditioning paradigm was used to train rats to hold their 
heads in a fixed position while testing their withdrawal responses to mechanical 
stimulation of the face. For this task, rats were placed in a start box and 
conditioned to traverse a plastic tube to drink an aqueous solution of 0.1 M 




position allowing von Frey monofilaments to be applied to specific locations, such 
as the masseter and periorbital region. While performing this task, rats consumed 
less than 2 mL of the sucrose solution, amounting to less than 10% of their daily 
water consumption. The amount of fluid required to alter sensory thresholds is 
over 1000 times this volume (Kanarek et al., 2001). The rats were not restrained 
in any way. Threshold withdrawal was assessed using a 4 g von Frey 
monofilament to test for mechanical allodynia on both the ipsilateral periorbital 
region and a 4 g von Frey monofilament on the ipsilateral masseter region. 
Previous studies using a 4 g von Frey monofilament demonstrated this procedure 
is sensitive enough to detect changes in withdrawal responses due to 
inflammation or estrogen status (Liverman et al., 2009a; Liverman et al., 2009b).  
Open-field locomotor activity 
General open-field locomotor activity was measured using an actimeter 
arena (BASi, San Diego CA). The apparatus utilizes high sensitivity force 
transducers coupled to the four corners of a rigid, low-mass floor to monitor and 
track the subject’s locomotor activity. Software processes the force-location data 
and provides detailed analysis of locomotor behaviors including distance 
traveled, bouts of low mobility, spatial confinement, and stereotypy. These 
position and force measurements are captured by the actimeter hardware and 
processed by accompanying software according to formulas developed by Dr. 
Stephen Fowler at the University of Kansas (Fowler et al., 2001). Briefly, distance 
traveled is calculated by summing distance over a set time period (5 minutes) 




of low mobility are scored when the center of force defined did not move beyond 
a radius of 15 mm within a 10 second period. The spatial confinement score was 
designed to compare a test rat to a theoretical rat that visits every sector of the 
arena in a given time period. This value is essentially the standard deviation of 
the rat’s movement from an evenly distributed theoretical value. If the center of 
force does not move beyond a single sector, a maximum spatial confinement 
score of 100 is recorded. The aggregate score is the sum of individual scores 
over 5 minutes. Focused energy is calculated by computing the weighted 
average of the force variance over a 5 minute period. Taken together, these 
measures provide quantitative assessments of several aspects of routine animal 
behavior. 
Hind paw testing 
Mechanical withdrawal thresholds were measured using an electronic von 
Frey apparatus (Model 2390; IITC Inc., Woodland Hills, CA). The animals were 
brought to the testing room and allowed to acclimate for at least 30 minutes prior 
to initiating the test. Following this acclimation period, the rats were placed in 
individual Plexiglas chambers located atop a steel mesh table and allowed to the 
environment for 15 minutes. After acclimation, the electronic von Frey filament 
was applied perpendicular to the surface of the hind paw. Mechanical pressure 
from the filament was applied until the animal exhibited a withdrawal behavior, 
including one of the following: movement of the paw away from the stimulus, 
shaking of the paw, and biting or licking of the paw. The absence of all of these 




to the filament automatically records the maximum force that applied to the paw. 
A measurement was taken three times at 2 to 5 minute intervals. The results 
were averaged to determine the mechanical withdrawal threshold to the nearest 
gram. All mechanical threshold testing was performed 2 hours following 
application to the dura of IS or vehicle. A total of 6 testing sessions were 
performed during the pre-surgical baseline, post-surgical baseline, and treatment 
days 1, 2, 3, and 6.  
Statistical analysis 
A two-way repeated-measures ANOVA with a Holm-Sidak post hoc 
comparison and confidence intervals was used to compare groups. The data 
were examined for non-normality and equal variance. Differences between 
groups are considered significant with a two-sided alpha level of 0.05. SigmaStat 
3.5 (Systat Software Inc., Chicago, IL) was used for data analyses. 
 Aim 2 methods 
Control animals 
 In addition to the vehicle control and IS groups animals mentioned in 
general methods this aim used male (n = 6) and female (n = 6) naïve control 
animals for baseline gene expression comparisons. 
Animal sacrifice 
Animals were sacrificed after undergoing behavioral testing, approximately 
20 minutes after receiving the final administration to the dura of vehicle or 




surfaces were thoroughly cleaned with RNaseZap (Applied Biosystems/Ambion, 
Austin, TX). The ipsilateral and contralateral dura, medulla and trigeminal ganglia 
were dissected and isolated under sterile conditions. All tissue samples were 
immersed immediately in RNALater (Applied Biosystems/Ambion, Austin, TX) 
and placed into 4° C refrigerator to preserve the mRNA for isolation.  
Quantitative real-time polymerase chain reaction (qRT-PCR) 
An RNA analysis was used to measure CGRP receptor (RAMP-1, CLR 
and RCP) gene expression in dura, trigeminal ganglia, and medulla. Total RNA 
was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions and was treated with DNaseI to remove any 
contaminating DNA. The cDNA was synthesized using 10 μg total RNA from 
each sample and random hexamers in a Taqman reverse transcription reaction 
(Applied Biosystems, Foster City, CA, USA). Expression of CGRP, RAMP1, CLR, 
and RCP mRNA was analyzed by real-time PCR using SYBR Green dye. The 
cDNA and gene-specific primers (Table 3) were added to SYBR Green PCR 
Master Mix (SYBR Green I Dye, AmpliTaqDNA polymerase, dNTPs mixture, 
dUTP, and optimal buffer components; Applied Biosystems, Foster City, CA, 













CGRP F –CTGTCACTGCCCAGAAGAGATC 
R -CAAAGTTGTCCTTCACCACACC 
101bp  












Table 3. qRT-PCR primers 
The PCR reactions were conducted in triplicate and the amplified 
transcripts quantified with the comparative double-delta threshold cycle (ΔΔCt) 
method using expression of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as an internal control. The resulting amplicon product was visualized 
on agarose gel to check size (and reaction specificity) and to confirm results. A 
published method for statistical analysis of real-time qRT-PCR data was 
employed (Pfaffl et al., 2002). 
Statistical analysis 
The rats were randomly assigned to the experimental and control groups. 
A student’s t-test was used to compare groups. The data were examined for 
evidence of non-normality and equal variance. Differences between groups are 
considered significant with a two-sided alpha level of 0.05. SigmaStat 3.5 (Systat 
















Locomotor activity and mechanical facial allodynia are modulated in 
a sex-dependent manner in response to inflammation of the dura mater in a 
rat model of migraine. 
Abstract  
The objectives of this study were to develop a preclinical behavioral model 
of chronic migraine for the purpose of testing sensory and motor behaviors 
relevant to International Headache Society (IHS) diagnostic criteria, and to 
determine whether there are sex differences in pain-related behaviors between 
male and female rats. 
Most previous animal studies of migraine employed electrophysiological 
techniques to assess neuronal sensitization, but in the present study changes in 
routine physical activity and mechanical sensitivity of facial regions were 
measured in response to inflammatory soup (IS) induced dural inflammation. 
Application to the dura of IS or control vehicle was performed 3 
times/week for a total of 8 applications. Locomotor activity was assessed using 
force plate actimetry during and following application of the IS or vehicle, and 
periorbital and masseter sensory testing was performed 20 min post-application 
to measure allodynia.  
These measurements revealed pronounced sex differences with regard to 
these measures. Thus, although both males and females showed behavioral 
effects following IS application, females were affected at the lower dose and had 




mobility, and spatial confinement. Moreover, females showed an increase in 
behavioral changes with increased dose of IS. Both males and females develop 
allodynia and in females distance traveled correlated with allodynia severity. 
This study demonstrates sex-related changes in locomotor activity 
associated with application of IS to the dura and the potential value of using 
International Headache Society diagnostic criteria to guide development of 
rodent models of migraine.  
Results 
Behavioral responses during onset of application of IS 
Locomotor activity measurements during application of the IS were 
designed to measure changes in routine activity at the onset of the headache 
(onset phase). Measurements of total distance traveled provided spatial 
quantification of these changes, i.e. a quantitative measure of ambulation (Figure 
5A). Male 10 μL groups showed no difference in the distance traveled in the 5 
minutes during application while the female group receiving 10 μL IS traveled 
less distance than control animals during the infusion (P < .001). Both the male 
and female 20 μL IS groups traveled less distance than vehicle controls in the 
same period (male 20 μL P < .05, female 20 μL P < .01). A dose effect was noted 
when comparing the female 10 μL and female 20 μL groups. The female 20 μL 
group that received IS were less active than female 10 μL group that received IS 
as measured by total distance traveled (P < .05). These data demonstrate that 
females are sensitive to the effects of IS in a dose-dependent manner and 




Quantification of bouts of low mobility assessed the temporal component 
of inactivity in response to IS treatment, i.e. time spent remaining inactive. Male 
10 μL IS groups showed no change in time spent inactive when compared to 
control animals during the IS infusion (Figure 5B), whereas the female 10 μL IS 
group spent more time inactive than did their vehicle control cohorts (P < .01). 
There was no significant difference between the male 20 μL group and female 20 
μL IS groups and their control cohorts. A sex difference was noted with respect to 
bouts of low mobility. Thus, at 10 μL doses of IS, females showed more bouts of 
low mobility as compared with vehicle controls than males, indicating that IS 
causes greater inactivity in females than males.  
Spatial confinement measurements quantify the area explored; i.e., with a 
high spatial confinement measure, animals confined their movement to their 
immediate vicinity and did not explore the whole arena. Normally, rats spend 
much of their time exploring a new environment and relatively little time 
remaining in a confined area. Thus, an increase in the spatial confinement score 
represents a change in routine activity. While the males 10 μL IS group were not 
found to differ from their vehicle control cohorts, the female 10 μL IS group 
displayed a higher spatial confinement score than controls (Figure 5C). That is, 
the females explored less area than the controls (P < .001). Male 20 μL and 
female 20 μL IS groups explored less area than did 20 μL vehicle control animals 
(P < .05 and P < .01 respectively). Only the male 20 μL, but both the female 10 
μL and 20 μL IS groups displayed higher confinement scores than their 




regard to the behavioral endpoint.  
Focused energy was used to quantify the amount of restless activity that 
occurs while the animal is stationary (Figure 5D). Male and female groups 
receiving 10 μL IS were not different from controls with regard to this measure. In 
contrast, male and female groups receiving 20 μL IS displayed a lower focused 
energy score than did vehicle control animals (P < .005 and P < .05 respectively). 
It is noteworthy that the control rats increased their focused energy scores over 
time, while the IS rats remained relatively immobile.  
Behavioral response following application of IS 
Locomotor activity measurements in the period starting 10 minutes after 
the infusion of IS or vehicle were designed to measure the persistence of 
changes in routine activity. In this period, the male 10 μL IS group showed no 
change in distance travelled when compared with vehicle controls (Figure 6A), 
while the female 10 μL IS group traveled less distance than vehicle controls in 
the period following infusion (P < .001). Neither the male 20 μL nor the female 20 
μL IS groups showed any statistical difference in distance traveled as compared 
to the vehicle treated groups. Thus, the female 10 μL group showed the most 
persistent changes in distance traveled following IS treatment.  
Vehicle and IS treatment in the male 10 μL group produced no statistical 
difference in bouts of low mobility during the persistence phase (Figure 6B). On 
the other hand, the female 10 μL IS group spent less time exploring the 
environment as compared to vehicle control animals (P < .001). Male 20 μL and 




during this period as compared to controls. As with the earlier behavioral tests, 
the female 10 μL IS group showed the most persistent effects.  
The male 10 μL IS group showed no changes in the spatial confinement 
metric when compared to vehicle controls (Figure 6C), while the female 10 μL IS 
group explored less area than controls (P < .0005). Male 20 μL and female 20 μL 
IS groups showed no changes in the area they explored as compared to vehicle 
controls. Thus, the female 10 μL IS animals was the only group showing 
persistent effects with respect to this measure. 
The male 10 μL IS group was no different with regard to its focused 
energy score as compared to vehicle control animals (Figure 6D), whereas, in 
contrast, the female 10 μL IS group displayed lower focused energy score (P < 
.005). Both the male 20 μL and female 20 μL IS groups receiving showed higher 
focused energy scores than control animals (P < .05 and P < .05 respectively). In 
this case, both 20 μL groups displayed persistent changes in focused energy with 
the 10 μL females showing changes in focused energy in the persistence phase 
but not in the onset phase.  
Facial allodynia following IS treatment 
Mechanical testing of the periorbital region measured sensitization of the 
first division of the trigeminal nerve (Figure 7A). The male 10 μL IS group showed 
significant allodynia of the periorbital region only on testing day 5 (P < .05) as 
compared to controls, with the male 20 μL IS group showing significant periorbital 
allodynia when compared with vehicle cohorts on testing days 3, 4, 5 and 7 (P < 




compared with their vehicle cohort on days 4, 5, 6 and 7 (P < .05). Thus, for the 
10 μL IS groups, females showed more allodynia than males, but in the 20 μL 
groups, males showed more allodynia than females.  
Mechanical testing of the masseter region measured sensitization of the 
third division (mandibular branch) of the trigeminal nerve (Figure 7B). The male 
10 μL IS group showed no allodynia during mechanical stimulation of the 
masseter region in comparison with vehicle controls, although significant 
allodynia was noted in the male 20 μL IS group on testing days 1, 3, 4, and 5 (P 
< .05). In contrast, the female 10 μL IS group experienced allodynia during 
mechanical stimulation of the masseter region only on testing days 5 and 7 (P < 
.05). Thus, the male 20 μL IS group showed the greatest allodynia in the 
masseter region under these conditions.  
Interictal behavioral response (48 hours) 
Locomotor activity measurements 48 hours after the infusion of vehicle or 
IS were designed to measure longer-term changes in routine activity over the 
course of the 2.5 week experiment. The male and female 10 μL IS groups 
displayed no statistically significant difference in distance traveled in the interictal 
period over the course of the experiment as compared to the 10 μL vehicle 
controls (Figure 8A). The male 20 μL IS group showed a decrease in distance 
traveled in the interictal period as compared to the vehicle controls (P < .05) over 
the course of the experiment. This contrasts with the female 20 μL IS subjects 
who showed difference in distance traveled as compared to controls. Thus, the 




distance traveled over the 2.5 week experiment.  
The male 10 μL IS group showed no statistical difference in changes in 
bouts of low mobility with respect to controls (Figure 8B), whereas the female 10 
μL IS group displayed a statistically significant increase in the number of bouts of 
low mobility when compared to controls (P < .05). Neither the male nor female 20 
μL IS groups demonstrated any statistical differences as measured by bouts of 
low mobility during the interictal period (Figure 8B). Thus, the female 10 μL IS 
group showed the most significant interictal changes in bouts of low mobility.  
 Neither the male nor the female 10 μL or 20 μL IS groups showed any 
difference in spatial confinement when compared to vehicle control animals 
(Figure 8C).The male and female 10μL IS groups did not show any difference in 
the focused energy score when compared to vehicle control animals (Figure 8D), 
although differences were noted compared to controls in both the male and 
female 20 μL IS groups (both P < .05).  
Interictal facial allodynia (48 hours) 
Mechanical testing of the periorbital region measured sensitization of the 
first division (ophthalmic branch) of the trigeminal nerve during the interictal time 
period (48 hours post application of IS). Neither the male nor female 10 and 20 
μL IS groups showed any significant allodynia in this facial region (Figure 9A). 
Mechanical testing of the masseter region measured sensitization of the third 
division (mandibular branch) of the trigeminal nerve (Figure 9B). None of the 





Correlation of locomotor and allodynia data 
In female subjects, onset phase distance traveled is highly correlated with 
interictal periorbital mechanical facial allodynia (Figure 10). Following a general 
linear fit, a goodness of fit analysis was performed using an ANOVA F-test. The 
correlation is statistically significant with a P = .0003. There was no statistical 
correlation when comparing onset phase distance traveled and interictal 
periorbital mechanical facial allodynia. 
Hind paw testing 
There was no significant difference in hind paw withdrawal thresholds 
between the groups receiving IS and vehicle, suggesting no allodynia in this 







Figure 5. Inflammatory soup decreases locomotor activity in onset phase. 
A) Distance traveled measurement: millimeters of distance traveled 
between t = 0 and t = 5 minutes. B) Bouts of low mobility: number of ten-second 
periods of inactivity between t = 0 and t = 5 minutes. C) Spatial confinement 




minutes. D) Focused energy: unit measure of activity while animal remains 
stationary between t = 0 and t = 5 minutes. X-axes show number of treatments. 
For each animal, 10 μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 (closed 
circles) or inflammatory soup (1 mM histamine, serotonin, bradykinin and 0.1 mM 
PGE2 in PBS) pH 5.5 (open circles) was delivered to the surface of intact dura via 
cannula. Male 10 μL vehicle group, n = 5; male 10 μL IS group, n = 5; female 10 
μL vehicle group, n = 9; female 10 μL IS group, n = 7; male 20 μL vehicle group, 
n = 3; male 20 μL IS group, n = 5; female 20 μL vehicle group, n = 3; female 20 
μL IS group, n = 5. Standard error is shown in error bars. # indicates a statistical 









Figure 6. Inflammatory soup decreases locomotor activity in persistence phase. 
A) Distance traveled measurement: millimeters of distance traveled 
between t = 10 and t = 15 minutes. B) Bouts of low mobility: number of ten-
second periods of inactivity between t = 10 and t = 15 minutes. C) Spatial 
confinement score: unit measure with inverse relation to area explored between t 




animal remains stationary between t = 10 and t = 15 minutes. X-axes show 
number of treatments. For each animal, 10 μL or 20 μL phosphate-buffered 
saline (PBS) pH 7.4 (closed circles) or inflammatory soup (1 mM histamine, 
serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 (open circles) was 
delivered to the surface of intact dura via cannula. Male 10 μL vehicle group, n = 
5; male 10 μL IS group, n = 5; female 10 μL vehicle group, n = 9; female 10 μL IS 
group, n = 7; male 20 μL vehicle group, n = 3; male 20 μL IS group, n = 5; female 
20 μL vehicle group, n = 3, female 20 μL IS group, n = 5. Standard error is shown 











Figure 7. Inflammatory soup induces facial allodynia. 
A) Primary division allodynia: Withdrawal scores in response to 
monofilament (4g) stimulation of the periorbital region. B) Secondary division 
allodynia. Withdrawal scores in response to monofilament (4g) stimulation of the 
masseter. Over the course of testing the withdrawal scale measures the 
maximum withdrawal as a score of 15 and no response as a score of 0. X-axis 
shows number of treatments. For each animal, 10 μL or 20 μL phosphate-
buffered saline (PBS) pH 7.4 (closed circles) or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 (open circles) 
was delivered to the surface of intact dura via cannula. Male 10 μL vehicle group, 
n = 5; male 10 μL IS group, n = 5; female 10 μL vehicle group, n = 9; female 10 
μL IS group, n = 7; male 20 μL vehicle group, n = 3; male 20 μL IS group, n = 5; 




is shown in error bars. # indicates a statistical significance with P < .05, * 











Figure 8. Inflammatory soup decreases routine activity interictally. 
A) Distance traveled measurement: difference in millimeters of distance 
traveled between post-surgical baseline and treatment day 8. B) Bouts of low 
mobility: difference in number of ten second periods of inactivity between post-
surgical baseline and treatment day 8. C) Change in spatial confinement score 
between post-surgical baseline and treatment day 8. D) Change in focused 
energy score between post-surgical baseline and treatment day 8. For each 
animal, 10 μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 (closed circles) 




in PBS) pH 5.5 (open circles) was delivered to the surface of intact dura via 
cannula. Male 10 μL vehicle group, n = 5; male 10 μL IS group, n = 5; female 10 
μL vehicle group, n = 9; female 10 μL IS group, n = 7; male 20 μL vehicle group, 
n = 3; male 20 μL IS group, n = 5; female 20 μL vehicle group, n = 3, female 20 
μL IS group, n = 5. Standard error is shown in error bars. # indicates a statistical 
significance with P < .05, * indicates P < .005. Data are shown as a box plot with 
a line within the box representing the 50th percentile or median, while the 
boundary of the box closest to zero indicates the 25th percentile and the 
boundary of the box farthest from zero indicates the 75th percentile. The 





Figure 9. Inflammatory soup does not illicit interictal allodynia. 
A) Primary division allodynia: Withdrawal scores in response to 
monofilament (4g) stimulation of the periorbital region. B) Secondary division 
allodynia. Withdrawal scores in response to monofilament (4g) stimulation of the 
masseter. Change calculated as difference between post-surgical baseline and 
treatment day 8. Over the course of testing the withdrawal scale measures the 
maximum withdrawal as a score of 15 and no response as a score of 0. For each 
animal, 10 μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 (closed circles) 
or inflammatory soup (1 mM histamine, serotonin, bradykinin and 0.1 mM PGE2 
in PBS) pH 5.5 (open circles) was delivered to the surface of intact dura via 
cannula. Male 10 μL vehicle group, n = 5; male 10 μL IS group, n = 5; female 10 
μL vehicle group, n = 9; female 10 μL IS group, n = 7; male 20 μL vehicle group, 
n = 3; male 20 μL IS group, n = 5; female 20 μL vehicle group, n = 3, female 20 
μL IS group, n = 5. Standard error is shown in error bars. # indicates a statistical 




a line within the box representing the 50th percentile or median, while the 
boundary of the box closest to zero indicates the 25th percentile and the 
boundary of the box farthest from zero indicates the 75th percentile. The 





Figure 10. In female subjects, onset phase distance traveled is highly correlated 
with interictal periorbital mechanical facial allodynia. 
X-axis shows interictal periorbital withdrawal score. Withdrawal scores in 
response to monofilament (4g) stimulation of the periorbital region during 
interictal period on Day 8. Y-axis shows distance traveled. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 (closed circles) or 
inflammatory soup (1 mM histamine, serotonin, bradykinin and 0.1 mM PGE2 in 
PBS) pH 5.5 (open circles) was delivered to the surface of intact dura via 
cannula. Female 10 μL vehicle group, n = 5; female 10 μL IS group, n = 6; 
female 20 μL vehicle group, n = 3, female 20 μL IS group, n = 5. The data are 
shown with a general linear regression with a goodness of fit analysis performed 





Figure 11. Inflammatory soup does not illicit ipsilateral hind paw allodynia. 
Withdrawal threshold values recorded in response stimulation of the hind 
paw by electronic von Frey apparatus. X-axis shows number of applications. Y-
axis shows withdrawal threshold in grams. For each animal, 20 μL phosphate-
buffered saline (PBS) pH 7.4 (closed circles) or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 (open circles) 
was delivered to the surface of intact dura via cannula. Withdrawal testing was 
performed 2 hours after application. Female 20 μL vehicle group, n = 3, female 
20 μL IS group, n = 5. Standard error is shown in error bars. # indicates a 





This is the first study to demonstrate that changes in behavioral activity 
occur during dural inflammation in a preclinical model of migraine. Using 
actimetry, it was found that animals receiving IS display a decrease activity 
similar to that observed during migraine attacks in humans (Kelman, 2006; 
Martins et al., 2006). These findings provide face validity for this animal model as 
useful tool for studying the behavioral and physiological changes associated with 
migraine. 
Previous studies demonstrated that IS sensitizes the trigeminal system 
(Kessler et al., 1992; Steen et al., 1992; Knyihar-Csillik et al., 2000; Ter Horst et 
al., 2001; Burstein and Jakubowski, 2004; Jakubowski et al., 2007; Zhang et al., 
2007a). Clinically, a change in routine activity is used as a key diagnostic 
criterion for migraine (IHS, 2004). Because changes in daily activity are 
associated with decreased quality of life, a goal of therapies is to maintain normal 
levels of activity. However, previous preclinical models of migraine have not 
measured this parameter. Furthermore, avoidance of routine activity is one of the 
most commonly reported migraine symptoms, with over half of migraineurs 
surveyed requiring bed rest to manage their migraine (Brandes, 2002). Another 
study found that each year there are 2.7 million days of work for men and 18.8 
million missed days for women in the United States because of migraine 
symptoms (Stang and Osterhaus, 1993). Avoidance of routine activity is a criteria 
for migraine diagnosis but there is no validated questionnaire/instrument for 




extent of headache severity with activity.  
In the present study, primary division facial mechanical allodynia was 
measured in the periorbital region (i.e. the same sensory dermatome as dura) 
and secondary allodynia was measured in the masseter region (different 
trigeminal dermatome from dura) as a measure of sensitization of the trigeminal 
pain pathway. Previous behavioral work assessed mechanical facial allodynia 
hours to days after application of IS, but did not thoroughly examined changes in 
activity within minutes of administration of the IS (Oshinsky and 
Gomonchareonsiri, 2007; Edelmayer et al., 2009; Wieseler et al., 2009). 
Periorbital region cutaneous allodynia, as measured by increased withdrawal 
scores, was significantly increased in females receiving inflammatory soup 
application, while males had significant sensitivity increases in response to 
stimulation of the masseter. Previous studies have shown allodynia of the 
periorbital region, but those studies did not test other regions of the face or 
compare males to females (Oshinsky and Gomonchareonsiri, 2007). 
A dose-response relationship was found with regard to the IS in locomotor 
measurements, including changes in distance traveled and spatial confinement in 
females (Figure 5A and 5C). Others have shown dose responsive decreases in 
mechanically stimulated firing thresholds of C-unit and A-delta neurons in the 
dura in response to 5-HT, histamine, and PGI2 (Zhang et al., 2007a). In the 
present study, although the molar equivalents (10 and 20 pmol equivalents for 5-
HT and histamine) are at the upper range of those investigated by Zhang et al. 




IS constituents acting on dural C and A-delta fibers. 
 The results of this study demonstrate that males and females show 
differences in their response to IS application to the dura. A 10 μL application of 
IS decreased activity in female but not male rats, as measured by decreased 
distance traveled, increased bouts of low mobility, and increased spatial 
confinement. This finding is of particular interest in that migraine, like a number of 
pain conditions, is more prevalent in females than males (Greenspan et al., 2007; 
Bigal and Lipton, 2009). An explanation for this may be provided by the finding 
that regulation of nociceptive sensitization in the trigeminal ganglia is strongly 
linked to estrogen (Flake et al., 2005; Puri et al., 2005; Liverman et al., 2009a; 
Liverman et al., 2009b). In addition, the frequency and propagation speeds of 
cortical spreading depression, a condition thought to be linked to migraine with 
aura, is increased in cycling females as compared to males and ovariectomized 
females in a mouse model of familial hemiplegic migraine type 1 (Eikermann-
Haerter et al., 2009). It is unknown whether estrogen alters the dose-response 
characteristics of dural nociceptors. 
Data from the current work indicates that alteration of locomotor activity 
was not as robust when measured interictally as it is when measured 
immediately after administration of the IS. Changes that generally correlated with 
both acute changes (e.g. distance traveled was reduced in groups that received 
IS versus vehicle controls) and with differences in sex and dose differences (e.g. 
females showed changes at lower volumes of IS applied) were apparent. The 




and display less head and body movement even while standing still. In this 
animal model of chronic migraine, some effects of chronic IS application are 
apparent as long as 48 hours following application of the soup (Figure 8).  
Another model of chronic migraine revealed sustained interictal periorbital 
allodynia 48 hours after IS application (Oshinsky and Gomonchareonsiri, 2007). 
In the present study, the female 20μL IS group displayed the most pronounced 
periorbital allodynia (Figure 7), although it was not statistically significant when 
compared with changes noted in the control vehicle group. Studies of 
migraineurs that suffer 1-6 migraine attacks per month show significantly lower 
pain thresholds acutely when compared with interictal values (Burstein et al., 
2000a; Burstein et al., 2000b). 
None of the groups examined in this work showed interictal cutaneous 
peri-masseter allodynia, indicating that allodynia in this region, innervated by a 
separate, third division of the trigeminal nerve, may present acutely and subside 
interictally. Again, this finding is consistent with clinical research showing that 
facial mechanical pain thresholds decrease 63% acutely (4 hours following onset 
of headache) as compared to interictal values (Burstein et al., 2000a).  
In female subjects, the distance traveled is highly correlated with interictal 
periorbital mechanical facial allodynia. Although interictal allodynia did not 
develop following chronic application of IS in any of the groups studied as 
compared to vehicle control, it was highly correlated with the decrease in routine 
activity noted during the onset phase (Figure 10). This connects the new assay 




allodynia as a migrainous end point. 
In contrast with other reports, no increase in hind paw mechanical 
sensitivity was observed following application to the dura of inflammatory soup 
(Edelmayer et al., 2009; Wieseler et al., 2009). There are several possible 
explanations for this difference. One is that females were tested in the present 
work, whereas in previous studies only males were examined. Secondly, the IS 
application in the current work was unilateral, as opposed to the bilateral 
administration employed by some others (Wieseler et al., 2009). Moreover, hind 
paw allodynia in a model of unilateral dural inflammation described in a previous 
report was in response to twice the concentration of IS used in the present study 
(Edelmayer et al., 2009), and the IS was administered repeatedly over two weeks 
in the current work, whereas others have administered it only once or twice 
before measuring a response (Edelmayer et al., 2009; Wieseler et al.). 
 Others have shown the magnitude of force required to elicit hind paw 
withdrawal responses is considerably different from those reported in the present 
study. The work reported herein shows baseline withdrawal thresholds of 
approximately 40 g, which is consistent with forces required for hind paw 
withdrawal reported by others (Hernstadt et al., 2009; Ito et al., 2009). Other 
studies using measurements of hind paw withdrawal in models of dural 
inflammation have reported baseline force withdrawal thresholds ranging from 15 
g (Edelmayer et al., 2009) to 3.16 g (Wieseler et al., 2009) of force. A response 
to a force in the range of 3 g is similar to the withdrawal threshold seen following 




Several clinical studies have identified extracephalic allodynia in 
migraineurs (Tfelt-Hansen et al., 1981; Burstein et al., 2000b; Ashkenazi et al., 
2007; Guy et al., 2009; Kalita et al., 2009). These studies often tested the 
forearm region. While a population-based study report that 63% of migraineurs 
experience allodynia during their migraine attacks (Lipton et al., 2008) this 
dropped to 8% to 49% when considering only those presenting with extracephalic 
allodynia (Guy et al., 2009; Kalita et al., 2009). Most extracephalic allodynia is 
thermal, not mechanical (Burstein et al., 2000b; Guy et al., 2009). One group 
reported that extracephalic allodynia correlates with more severe and less 
frequent headache episodes than cephalic allodynia alone (Guy et al., 2009). 
Extracephalic allodynia has also been reported in fibromyalgia and has been 
shown to be mostly thermal (Smith et al., 2008). Migraine is co-morbid with 
fibromyalgia in 22-36% of patients (Ifergane et al., 2006; de Tommaso et al., 
2009). Indeed, there is speculation that migraine and fibromyalgia share 
pathophysiology and are components of the same disorder (Centonze et al., 
2004; Ifergane et al., 2006).  
It is impossible fully to explain all of the differences between the present 
findings and earlier reports. Nonetheless, the present findings indicate there may 
be sex related differences in extracephalic allodynia or, perhaps, subtle effects 
related to method or chronicity of application to the dura that can influence the 
appearance of extracephalic allodynia. 
In conclusion, the results of this study demonstrate significant decreases 




female rats in response to application to the dura of IS in a model of chronic 
migraine. The changes in locomotor activity occur at lower doses of IS, are more 
persistent, and are dose-related in females but not males. While the differences 
in the overall pattern of allodynia and changes in locomotion noted in this study 
are complex, they suggest that females are more sensitive to dural inflammation 
and the effects of dural inflammation may be longer lasting in females. This 
model provides a new tool to further investigate the reason for sex differences in 
migraine and a more refined analysis of the locomotor and pain-related behaviors 






V. Changes in Gene Expression of CGRP and Receptor Components in a 










Expression of genes encoding for CGRP and CGRP-related receptor 
components will be modulated in a sex-dependent manner in response to 
inflammation of dura mater in a rat model of migraine. 
Abstract 
The objectives of this study were to determine the differences in the pain-
evoked expression pattern of genes encoding CGRP and components of its 
receptor in regions of the trigeminal pathway (trigeminal ganglion and medulla) 
following application to the dura of inflammatory soup (IS), to study sex 
differences in expression of these genes, and to attempt to correlate the 
migraine-like behavioral changes in a preclinical rat model of migraine to any 
changes in gene expression. 
The vasoactive substance, calcitonin gene related peptide (CGRP) is 
thought to be an important mediator of migraine. The CGRP receptor consists of 
a G–protein coupled calcitonin-like receptor (CLR), a receptor activity-modifying 
protein (RAMP1), and a receptor component protein (RCP). Following chronic IS 
application to model migraine, real-time polymerase chain reaction was used to 
quantify the expression of mRNA for CGRP, RAMP1, CLR, and RCP.  
In the medulla, females displayed higher baseline gene expression of 
CGRP and lower baseline expression of RAMP1, CLR, and RCP than males, 
with CLR and RCP being induced in all of the experimental conditions. In the 
trigeminal ganglia, females displayed lower baseline expression of RAMP1, CLR, 




induction in gene expression than males. In males, RCP gene expression was 
increased in the trigeminal ganglia of animals displaying migraine-like behaviors. 
These findings provide new evidence that changes in the expression of CGRP-
related genes may underlie the differences in prevalence of migraine in men and 
women. 
Results 
This portion of the study focuses on CGRP and related receptors and how 
they are affected by dural inflammation. Given the data suggesting a relationship 
between CGRP and the symptoms of migraine, these experiments were 
performed in an attempt to determine whether sex-related changes in the CGRP 
system my underlie the gender differences in the prevalence of this disorder. To 
this end, measurements were made in the changes in expression of qRT-PCR of 
CGRP, RAMP1, CLR and RCP in a new animal model of migraine headache.  
Sex differences 
 Sex-related differences in mRNA expression in the trigeminal ganglia 
(Figure 12) noted in the present study include significantly lower expression of 
mRNA in females than in males for RAMP1, CLR, and RCP (P = .008, P < .001, 
and P = .003, respectively) genes. In the medulla (Figure 13), sex-related 
differences were found in the significantly lower expression of mRNA in female 
subjects as compared to males for RAMP1, CLR, and RCP (P = .007, P = .002, 
and P = .001, respectively) genes, and a higher expression of CGRP in the 




Induction in gene expression in trigeminal ganglia in male rats 
 Gene expression of CGRP (Figure 14) is decreased in all experimental 
groups (male 10 μL vehicle, P = .008; male 10 μL IS, P = .008; male 20 μL 
vehicle, P = .024, and male 20 μL IS, P = .017) and gene expression of RAMP1 
(Figure 15) is decreased in the male 10 μL vehicle and male 10 μL IS groups (P 
< .001 and P = .011, respectively) as compared to controls. As for CLR 
expression (Figure 16), it is decreased in the male 10 μL vehicle and male 10 μL 
IS groups (P = .001 and P < .001) and increased in the male 20 μL vehicle group 
(P = .024) and male 20 μL IS group (P = .007) relative to the control subjects. 
Gene expression of RCP (Figure 17) is decreased in the male 10 μL vehicle (P = 
.004) and increased in the male 20 μL vehicle group (P = .029) and the male 20 
μL IS group (P = .004) as compared to controls. 
Induction in gene expression in medulla in male rats 
  The expression of the CGRP gene (Figure 18) is significantly lower in 
male subjects receiving 20 μL vehicle and 20 μL IS (P = .026 and P = .007), and 
RAMP1 expression (Figure 19) is significantly lower in males receiving 20 μL of 
IS compared with control male subjects (P = .002). It was also found that CLR 
expression (Figure 20) is lower in male 10 μL vehicle and 10 μL IS-treated 
groups than in controls (P = .026 and P = .004, respectively). Gene expression of 
RCP (Figure 21) is unchanged in all groups when compared to control subjects.  
Induction in gene expression in trigeminal ganglia in female rats 
 There is no statistical difference in gene expression for CGRP or RAMP1 




respectively). However, CLR expression (Figure 16) is higher in both the female 
20 μL vehicle group (P < .001) and the female 20 μL IS group (P = .004) as 
compared to controls, and gene expression of RCP (Figure 17) is higher in all 
groups as compared to control subjects (female 10 μL vehicle, P = .03; female 10 
μL IS, P = .015; female 20 μL vehicle, P = .048, and female 20 μL IS, P = .004). 
Induction in gene expression in medulla in female rats 
 In comparison to female control subjects, CGRP gene expression (Figure 
18) is significantly lower in female subjects receiving 20 μL IS (P = .042) and 
RAMP1 expression (Figure 19) is significantly higher in females receiving 10 μL 
of IS as compared about female control subjects (P = .020). In contrast, CLR 
expression (Figure 20) is higher in all groups, including vehicle treated groups, 
than in the untreated control group (female 10 μL vehicle, P = .004; female 10 μL 
IS, P = .002; female 20 μL vehicle, P = .024, and female 20 μL IS, P = .004). 
Gene expression of RCP (Figure 21) is also higher in all groups when compared 
to control subjects (female 10 μL vehicle, P = .03; female 10 μL IS, P = .003; 
female 20 μL vehicle, P = .024, and female 20 μL IS, P < .001).  
Gene induction in males displaying migraine-like behaviors 
Statistically significant behavioral changes noted with these animals 
(Stucky, 2010) were compared to the significant changes in detected in gene 
expression under the various treatment conditions. The results indicate that 
males show significantly decreased expression of RAMP1 in the medulla in the 
group receiving 20 μL IS (Figure 19), which also displayed migraine-like 




of RCP is significantly increased in trigeminal ganglia of the group receiving 20 
μL IS (Figure 17), which is also a group that displayed migraine-like behaviors 
(Stucky, 2010).  
Gene induction in females displaying migraine-like behaviors 
Females receiving 20 μL IS show a decrease in the expression of CGRP 
in the medulla (Figure 18) and those receiving 10 μL IS display an increased 
expression of RAMP1 (Figure 19). These groups displayed migraine like 





Figure 12. Baseline sex differences in CGRP-related gene expression in rat 
trigeminal ganglia 
Relative expression of genes of interest in the trigeminal ganglia as 
measured by qRT-PCR using ΔΔCt analysis to calculate relative expression. 
GAPDH was used as internal control. X-axis shows gene of interest. Y-axis 
shows relative expression. Animals are naïve control male or naïve control 
female Sprague-Dawley rats. Male group, n = 6 (black bars), female group, n = 6 
(white bars). Standard error is shown in error bars. # indicates a statistically 








Figure 13. Baseline sex differences in CGRP-related gene expression in rat 
medulla 
Relative expression of genes of interest in the medulla as measured by 
qRT-PCR using ΔΔCt analysis to calculate relative expression. GAPDH was used 
as internal control. X-axis shows gene of interest. Y-axis shows relative 
expression. Animals are naïve control male or naïve control female Sprague-
Dawley rats. Male group, n = 6 (black bars), female group, n = 6 (white bars). 
Standard error is shown in error bars. # indicates a statistically significant 









Figure 14. Sex differences in induction of gene expression of CGRP in rat 
trigeminal ganglia 
Relative expression of CGRP in the trigeminal ganglia as measured by 
qRT-PCR using ΔΔCt analysis to calculate relative expression. GAPDH was used 
as internal control. Average naïve male expression used as subject control. X-
axis shows treatment groups. Y-axis shows relative expression. For each animal, 
10 μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 
mM histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n =  5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 15. Sex differences in induction of gene expression of RAMP1 in rat 
trigeminal ganglia 
Relative expression of RAMP1 in the trigeminal ganglia as measured by 
qRT-PCR using ΔΔCt analysis to calculate relative expression. GAPDH was used 
as internal control. Average naïve male expression used as subject control. X-
axis shows treatment groups. Y-axis shows relative expression. For each animal, 
10 μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 
mM histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n = 5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 16. Sex differences in induction of gene expression of CLR in rat trigeminal 
ganglia 
Relative expression of CLR in the trigeminal ganglia as measured by qRT-
PCR using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n = 5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 17. Sex differences in induction of gene expression of RCP in rat trigeminal 
ganglia 
Relative expression of RCP in the trigeminal ganglia as measured by qRT-PCR 
using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n = 5; 10 μL  IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 18. Sex differences in induction of gene expression of CGRP in rat medulla 
Relative expression of CGRP in the medulla as measured by qRT-PCR 
using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n =  5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 






Figure 19. Sex differences in induction of gene expression of RAMP1 in rat 
medulla 
Relative expression of RAMP1 in the medulla as measured by qRT-PCR 
using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n = 5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 20. Sex differences in induction of gene expression of CLR in rat medulla 
Relative expression of CLR in the medulla as measured by qRT-PCR 
using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n = 5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





Figure 21. Sex differences in induction of gene expression of RCP in rat medulla 
Relative expression of RCP in the medulla as measured by qRT-PCR 
using ΔΔCt analysis to calculate relative expression. GAPDH was used as 
internal control. Average naïve male expression used as subject control. X-axis 
shows treatment groups. Y-axis shows relative expression. For each animal, 10 
μL or 20 μL phosphate-buffered saline (PBS) pH 7.4 or inflammatory soup (1 mM 
histamine, serotonin, bradykinin and 0.1 mM PGE2 in PBS) pH 5.5 was 
chronically delivered to the surface of intact dura via cannula for 8 applications. 
Male (black bars) naïve group, n = 6; 10 μL vehicle group, n =  5; 10 μL IS group, 
n = 5; 20 μL vehicle group, n = 3; 20 μL IS group, n = 5; Female (white bars) 
naïve group, n = 6; 10 μL vehicle group, n = 9; 10 μL IS group, n = 7; 20 μL 
vehicle group, n = 3, 20 μL IS group, n = 5. Standard error is shown in error bars. 
# indicates a statistically significant difference from the sex matched naïve 





 Studies by others have localized the protein expression of CGRP, RAMP1 
and CLR in the trigeminal pathway in male rats (Lennerz et al., 2008). In the 
trigeminal ganglia, CLR and RAMP1 are found on Schwann and satellite cells. 
The CLR, RAMP1 and CGRP are co-localized on trigeminal neurons and their 
central projections. In the spinal trigeminal nucleus of the medulla, because CLR, 
RAMP1 and CGRP are found on glomerular-shaped structures and not central 
glia or neuron cell bodies, it was concluded that primary afferent nerve endings 
are being labeled (Lennerz et al., 2008). In the present study, gene expression 
was evident in the medulla indicating that either mRNA was transported to the 
primary afferent fiber endings or that CGRP and its receptors are expressed in 
resident neurons or glia. 
The results of the current work reveal that mRNA for CGRP, RAMP1, CLR 
and RCP is expressed in both medulla and trigeminal ganglia, and there are 
significant sex differences in gene expression of CGRP and CGRP receptors, 
including sex-dependent changes in expression of these genes in response to 
the chronic application of IS to the dura. A concurrent study (Stucky, 2010) 
demonstrated sex-related IS-induced migraine-like behavioral changes in these 
same test subjects. 
It was found in this study that females have higher baseline gene 
expression of CGRP in the medulla than males (Figure 13), and that the 
expression of CGRP in the medulla declines following chronic application of IS to 




in males, although this appears to be due primarily to the volume of fluid placed 
on the dura, suggesting a volume effect in these subjects. Changes in CGRP 
protein levels have be influenced by female sex hormones (Lanlua et al., 2002; 
Pardutz et al., 2002; Yallampalli et al., 2002), which may account for the sex 
differences in gene expression observed in the present work. Little is known 
about gene expression of CGRP in the medulla or dorsal horn. Thus, these 
findings indicate that CGRP gene expression in the medulla is differentially 
regulated between sexes in a model of chronic migraine. 
In the medulla, females have lower baseline gene expression of RAMP1, 
CLR, and RCP than males (Figure 13), and CLR and RCP are induced by 
application of IS or vehicle to the dura in all of the experimental conditions 
(Figure 20 and Figure 21). The RAMP1 mRNA is induced by repeated application 
of 10 μL IS in females, whereas in males there appears to be a small, but 
statistically significant, IS-induced reduction in gene expression of RAMP1 
(Figure 19). Although RAMP1 and CLR are reported to be induced in 
reproductive tissues by ovarian steroids (Dong et al., 2003), little is known about 
their induction in the trigeminal system. As the female 10 μL IS group showed 
significant allodynia and the 10 μL IS male group did not, it is possible that the 
induction of RAMP1 in the brainstem may contribute to central sensitization.  
An increase in gene expression of CLR and RCP was noted in this study 
across all experimental female groups. A possible explanation for this is that a 
baseline inflammatory response to the cannula implantation surgery is sufficient 




others has shown that crainiectomy or parietal bone scoring alone is sufficient to 
produce mast cell degranulation, local dural histamine release, and edema, 
which might mimic in some ways the inflammation induced in the present study 
(Stokely and Orr, 2008).  
No baseline sex differences were observed in gene expression of CGRP 
in the trigeminal ganglia in the current study, although others have found more 
trigeminal CGRP-positive neurons in male rats as compared to females 
(Ambalavanar et al., 2003). In the present study, gene expression of CGRP in 
the trigeminal ganglia was decreased in male experimental groups but not in 
females following repeated application of IS to the dura. This effect was present 
across all experimental groups. While others have reported increases in CGRP 
gene expression from 30 minutes to 24 hours following a single injection of CFA 
in the masseter of male rats (Ambalavanar et al., 2006a), this is an acute 
response as opposed to chronic nature of the present work.  
CGRP levels in blood plasma and DRGs are increased during pregnancy 
and in ovariectomized animals receiving sex hormones (Lanlua et al., 2002). 
Estrogen has been shown to increase activation of intracellular signaling 
pathways in the trigeminal ganglia (Liverman et al., 2009a), pathways known to 
be involved in activating CGRP transcriptional enhancers (Durham and Russo, 
2003). This may be, in part, responsible for why in the present study there are 
reductions in gene expression of CGRP in trigeminal ganglia in response to 
repeated IS application in males but not females. 




CGRP receptors RAMP1, CLR, and RCP in the trigeminal ganglia than males. 
Expression of RAMP1 in the trigeminal ganglia is decreased in males receiving 
10 μL applications of either IS or vehicle. Indeed, it was found that gene 
expression is subject to a volume effect in males, with reduction of RAMP1 
expression with a 10 μL volume, and an increase at 20 μL. Gene expression of 
CLR follows the same pattern as RAMP1. A small but significant volume effect 
on gene expression is also noted in females.  
The RCP protein is induced in males receiving 20μL applications of either 
IS or vehicle, being greatest in those repeatedly exposed to 20μL of inflammatory 
soup, a condition which also induces migraineous behaviors (Stucky, 2010). As 
for females, RCP gene expression is induced in all experimental groups. This 
could be in response to surgery, as previously described for RCP and CLR in the 
medulla. In the trigeminal ganglia, RAMP1, CLR and RCP are inducible 
especially in males and volume effects are present. This suggests a regulatory 
role for mechanically or osmotically active sensory channels in this region. Acid 
sensitive ion channel (ASIC) family channels, such as TRPV4 or voltage-gated 
sodium channels (Nav) family channels, such as Nav 1.8, are possible candidates 
for this role. For example, TRPV4 channels are known to be present in trigeminal 
ganglia, and their activation has been shown to increase the excitability of 
nociceptors through a protein kinase C (PKC)-dependent mechanism (Chen et 
al., 2009a). The ion channels, such as Nav 1.7, Nav 1.3 and Nav 1.8, are reported 
to increase excitability of the trigeminal nociceptors in much the same way (Chen 




activated in response to osmotic or mechanical changes in neurons co-
expressing RCP or CLR and whether there is a correlation in the expression of 
these genes. 
 In the present study, females displayed a greater dynamic range of 
induction in gene expression than males. Sex differences in baseline values of 
gene expression appear to prime females for a greater percentage change in 
CGRP receptor gene expression. For example, female CLR gene expression is 
increased 12.6-fold when comparing the naïve control group to the 20 μL IS 
group, while expression is increased only 2.2-fold in males. 
 The present findings also suggest greater induction in the trigeminal 
ganglia of males and more induction in the medulla in females in response to 
exposure to the IS. This suggests that migraine pathophysiology may occur more 
centrally in females, and that central sensitization may be more likely in females 
than males. This gene expression data correlates with the finding in a related 
study that there is more allodynia in females and it occurs in response to smaller 
volumes of IS than in males (Stucky, 2010). 
Taken together with the behavioral study, the results of these experiments  
support the possibility that sex differences in CGRP and CGRP receptor 
expression may be responsible for the increased prevalence of migraine in 
females. These data indicate that gene expression changes in CGRP and CGRP 
receptors are differentially regulated in a model of chronic dural inflammation, 









Summary of findings 
 A major aim of this dissertation project was to establish a model of 
migraine headache and use it to identify sex differences in behavior. The existing 
model was extended to encompass an IHS criterion for headache diagnosis in 
humans, namely, reduction in routine activity. Decreased locomotor activity and 
increased allodynia were noted in both sexes at a dose of 20 μL of IS to the dura, 
supporting the validity of the technique as a putative model for migraine. 
Using assays for mechanical facial allodynia and locomotor activity 
together allowed for assessment of the behavioral differences between males 
and females in their reactions to dural inflammation. The results revealed that 
both locomotor activity and mechanical facial allodynia are modulated in sex-
dependent manners in response to repeated applications of IS. In addition to 
higher dose treatment, females also showed effects at a dose of 10 μL IS, in 
accord with the fact that women are more likely to experience migraine than men. 
Females also showed allodynia in regions innervated by the ophthalmic division 
which is the same division of the trigeminal ganglia that innervates the site of 
dural inflammation. Males on the other hand demonstrated more allodynia in the 
peri-masseter region, innervated by the mandibular division of the trigeminal 
ganglia.  
Once the model was established and sex-differences in behavioral 
changes were identified, evaluation of baseline sex-dependent variations in gene 




performed to investigate whether expression of these genes changes in 
response to application of the IS. Significant findings showed lower CGRP 
receptor and higher ligand gene expression levels in females at baseline and 
greater percentage induction of receptors in females. More central changes were 
seen in females while the largest expression changes happened peripherally in 
males, and volume effects were present in both groups. Before addressing the 
implications of this work a discussion of limitations of the study is necessary. 
Limitations 
There are important behavioral correlates of migraine that this study did 
not attempt to measure. The two most prominent are photophobia and 
phonophobia. Both are included in the IHS diagnostic criteria and are adaptable 
to a rodent model. One laboratory has created mouse model of photophobia 
(Recober et al., 2009) and in models of acoustic startle have been used to study 
anxiety and stress (Davis et al., 1997; Walker et al., 2009) and could be adapted 
to use in a migraine model. 
The CGRP-related gene expression is one possible regulatory mechanism 
of sensitization, but there are many others. Migraine pathophysiology may be 
regulated at many points including gene expression, post-transcriptional 
processing, protein expression, ligand or receptor trafficking, ligand binding, and 
receptor signaling. This study investigated baseline expression and IS-induced 
changes at the mRNA level but did not thoroughly look at changes in protein. An 
attempt was made to perform protein quantification using western blot analysis 




bands that did not correspond to any published isoforms. Further functional 
studies could be performed to look at ligand binding and receptor signaling. It is 
feasible to look at G-protein signaling using GTPγs (Winter and McCarson, 2005) 
and preliminary studies have been performed with tissue from this study. With 
these limitations in mind, the model can be extended to new areas of research. 
Future directions 
 Using with the behavioral data and tissue that has been collected in this 
study it is possible to use additional qRT-PCR primers to perform additional 
analysis of other genes that may be involved in migraine. As mentioned 
previously genes that are involved in osmotic or mechanical signaling such as 
Nav 1.8, and TRPV4 may be induced by application of IS to the dura. Actimetry 
and qRT-PCR are both highly quantitative and data intensive methods and this 
study has produced a voluminous dataset of greater than 6,000 data points. A 
systems biology approach is well suited to analyze the data from this study. For 
example, principal component analysis could be used for data reduction to 
isolate the genes that change most independently from those that are highly 
interdependent. In this study linear regression analysis was used to determine 
correlations between genes and behavior, but it is likely that interactions are 
more complex than can be modeled using this technique. Further modeling can 
be performed to search for interactions that may be revealed by more 
sophisticated techniques. The many signaling motifs possible in the trigeminal 
system are likely to produce complex interactions that will be suitable for study 




The finding that application volume influenced gene expression was 
unexpected and indicates that application volume could significantly influence 
trigeminal activation. One strategy to investigate this phenomenon would be to 
serially increase volumes of vehicle (the present study investigated 2 different 
volumes) and measure behavioral effects. A second strategy would be to isolate 
volume effects from the IS effects by applying a constant volume of increasingly 
concentrated IS and measure behavioral changes. Certainly, CGRP related gene 
expression changes should be measured in these same groups.  
To further investigate the role of neurogenic inflammation and dural mast 
cells in migraine, the present model can be used with agents that eliminate the 
influence of resident dural mast cells through stabilization or depletion using 
pretreatment of the dura with the mast cell stabilizer sodium dicromoglycate 
(Markowitz et al., 1989) or with the mast cell depleting agent 48/80 (Marotta et 
al., 2009). 
 One of the most exciting future directions is to move beyond neurogenic 
inflammation and employ the model to study behavioral correlates and molecular 
changes in other processes involved in migraine pathogenesis and related 
disorders. Cortical spreading depression can be induced by applying KCl directly 
to the dura in rats (Colombo et al., 1973) and there is still considerable debate 
about how this biological effect and is involved in migraine (Pietrobon, 2005). The 
model could be adapted to study menstrual migraine by manipulating estrogen 
levels in rats through ovariectomy and estrogen replacement. Additionally, this 




associated with medication overuse of headache, a condition associated with a 
number of drugs used to treat migraine (Tepper and Tepper, 2010). In this 
condition, migraineurs find that increasing pharmacological treatment 
paradoxically increases the frequency of migraine attacks, and the migraine 
episodes become more resistant to therapy. This is most often encountered with 
opioid drugs (Bigal et al., 2004; Tepper and Tepper, 2010). Unfortunately, the 
incidence of mild traumatic brain injury is increasing in the U.S. population as 
soldiers return from serving in Iraq and Afghanistan (Afari et al., 2009). 
Development of a model of trauma induced headache would be especially 
relevant and can be investigated in this model by performing a mild traumatic 
brain injury prior to initiating neurogenic inflammation. Using the techniques in 
the current study each of these studies could be accomplished in a 
straightforward manner. 
 In the future, the model will be useful to investigate new drugs and 
therapies. CGRP antagonists are currently under development for use in 
migraine and new more effective therapies are needed for of migraine sufferers 
that have increased cardiovascular risk profiles or are not helped by existing 
therapies. The locomotor component of the behavioral model is highly 
quantitative and measures activity, which is an important functional outcome. 
This characteristic of the preclinical model may allow early detection of 






A major contribution from the present project was development of 
behavioral assays for a model of migraine that appear to be more robust than 
others. The measurements are highly quantitative and less susceptible to 
experimenter bias than previous measures of allodynia. By incorporating the 
actimeter and the ability to precisely quantify the level of ambulation and force 
variance using metrics such as distance traveled and bouts of low mobility this 
study allowed for an assessment in rats that is analogous to those clinical signs 
and symptoms used to diagnose humans as migraineurs. This strengthens the 
value of this preclinical model considerably. Reductions in locomotor activity 
were present in the model developed in the present study and that this reduction 
correlates with periorbital mechanical allodynia in females make for a significantly 
stronger preclinical model for investigating migraine pathophysiology and for 
testing therapeutic interventions.  
 The allodynia behavioral task presented in the present study has 
advantages over other models of facial mechanical testing in migraine (Oshinsky 
and Gomonchareonsiri, 2007; Edelmayer et al., 2009; Wieseler et al., 2009) 
because it does not require restraint of the rats and therefore the results are less 
confounded by the significant analgesic effects which have been reported in 
response to restraint (Botelho et al., 2010). 
 Evidence of increased expression of RCP in the trigeminal ganglia of 
males and of RCP in the medulla of females displaying migraine-like behaviors 




indicates trigeminal sensitization may involve CGRP signaling, which is a 
mechanism that is a major target of drug development. 
 This study identified major sex differences that are significant and have 
never been looked at before in migraine model, in both aspects of behavioral and 
molecular changes. The present study with this model has shown significant sex 
differences in susceptibility to migraine, with females displaying migraine-related 
behavioral responses at lower doses of the inflammatory soup than males, and 
with females displaying a greater persistence of effect than males. As the effects 
in female were dose-related, it appears they represent pharmacologically and 
physiologically relevant effects of the inflammatory agents contained in the IS. 
An important element of these findings is that females have a greater 
dynamic range of induction in gene expression. It appears that sex differences in 
baseline values of gene expression prime females for a greater percentage 
change in CGRP receptor gene expression than is the case for males. This 
change could be responsible for the greater susceptibility of females to migraine.  
Previous work in other organ systems revealed that gene and protein 
expression of RAMP1 and CLR are highly inducible in females, and that 17β-
estradiol inhibits expression, while progesterone stimulates expression of these 
proteins in the rat placenta during pregnancy (Dong et al., 2003). These 
hormone-related RAMP1 and CLR expression changes have also been observed 
in the rat mesenteric artery (Yallampalli et al., 2004). As it is also believed that 
CGRP plays an essential role in maintaining normal blood pressures in response 




2004). Perhaps it is necessary that the CGRP system be highly adaptable in 
females and a possible adverse effect of this adaptability may be increased 
susceptibility to trigeminal activation and migraine. 
While the mechanisms underlying migraine remain poorly understood, for 
the first time these results provide evidence that sex differences in the regulation 
of the expression of CGRP and CGRP receptors in migraine correlate with 
changes in migraine-like behaviors and may be responsible for the increased 
prevalence of migraine in females. As gene expression changes in CGRP and 
CGRP receptors are differentially regulated in this model of migraine, the results 
provide further evidence for their potential involvement in modulating pain and 
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